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aAPC    artificial antigen presenting cell 
Ab    antibody 
ACN    acetonitrile 
BSA    bovine serum albumin 
CA-125    cancer antigen 125 
CD     cluster of differentiation 
CRABP    cellular retinoic acid-binding protein 
CTL     cytotoxic T lymphocyte 
DC     dendritic cell 
DMSO   dimethylsulfoxide 
DNA     deoxyribonucleic acid 
ELISpot    enzyme linked immuno spot assay 
EOC     epithelial ovarian cancer 
ER     endoplasmic reticulum 
EYA2     eyes absent homolog 2 
Fa    formic acid 
FIGO    International Federation of Gynecology and Obstetrics 
FOLR1    folate receptor alpha 1 
FSC    forward scatter 
HLA     human leukocyte antigen 
ICS    intracellular cytokine staining 
IDO1     indoleamine 2,3-dioxygenase 1 
IFN    interferon 
IL     interleukin 
KLK     kallikrein 
LGALS1    galectin-1 
MHC    major histocompatibility complex 
MMP    matrix metalloproteinase 
MS     mass spectrometry 
MSLN    mesothelin 
MUC16   mucin 16  
OvCa    ovarian cancer 
PBMC    peripheral blood mononuclear cell 
8 
 
PMP    patients with malignant progression  
PNP    patients with no malignant progression 
PTTG    pituitary tumor transforming gene 
RNA     ribonucleic acid 
SSC    side scatter 
TAA     tumor-associated antigen 
TFA     trifluoroacetic acid 
Th1     T helper cell type 1 
TIL    tumor infiltrating lymphocyte 
TMEM158    transmembrane protein 158 
Treg    regulatory T cell 





This thesis is about the characterization of tumor-infiltrating lymphocytes (TILs) and 
the development of a therapeutic peptide-based anti-cancer vaccine against ovarian 
cancer. The thesis is divided into three parts. The first part is about tumor-infiltrating 
lymphocytes and their expression of co-inhibitory and co-stimulatory receptors on the 
cell surface. For a more precise differentiation CD8+ cytotoxic T cells were separated 
from CD4+ T cells and the latter were further differentiated into regulatory T cells and 
T-helper cells. The co-inhibitory and co-stimulatory receptors CD137, cytotoxic T 
lymphocyte protein (CTLA-4), lymphocyte activation gene 3 (LAG-3), programmed cell 
death protein 1 (PD-1) und T cell immunoglobuline (TIM-3) were analyzed separately 
in the three different groups of regulatory T cells, cytotoxic T cells and T-helper cells.  
To evaluate the expression levels of the co-receptors on tumor-infiltrating lymphocytes, 
they were compared to lymphocytes from the peripheral blood (PBMCs) of each patient 
and PBMCs from healthy donors. It was shown that most of the receptors remained 
absent or of low expression besides PD-1 that apparently plays a dominant role in the 
immunosuppressive tumor microenvironment. Besides PD-1, CD137 shows low to 
moderate expression across the different patients being an interesting target for 
immunotherapy.  
The second part focusses on the isolation of natural HLA ligands from ovarian tumor 
tissue. The eluted peptides and their respective source proteins were compared to 
source proteins and their peptides of benign ovarian tissue and a database that 
contains autopsies of different benign tissues. Through comparative profiling tumor-
exclusive source proteins were determined. 
At the end of the thesis these naturally presented tumor-exclusive ligands were used 
to treat patients who have no further therapy options. The treatment was able to induce 
HLA class I and HLA class II mediated reactions. The reactions were monitored 
through the course of therapy via IFN-γ ELISpot. Overall three patients were analyzed. 
In the first patient treated, we were able to induce a HLA class II mediate immune 
response. We were able to induce an HLA class I and II mediated immune response. 
The third patient has shown a pre-existing immune response against one HLA class I 





Die vorgelegte Doktorarbeit befasst sich mit der Charakterisierung von 
tumorinfiltrierenden Lymphozyten und der Entwicklung einer therapeutischen 
peptidbasierenden Krebsimpfung beim Ovarialkarzinom. Der erste Part befasst sich 
mit tumorinfiltrierenden Lymphozyten und deren Expression von costimulatorischen 
und coinhibitorischen Rezeptoren auf der Zelloberfläche. Für eine präzisere 
Auftrennung wurden CD8+ zytotoxische T-Zellen von CD4+ T-Zellen unterschieden 
und diese wiederum wurden ihrer Funktion ein weiteres Mal unterteilt in T-Helferzellen 
und regulatorische T-Zellen. Die kostimulierenden und koinhibierenden Rezeptoren 
CD137, zytotoxisches T-Lymphozyten Protein 4 (CTLA-4), Lymphozyten-
Aktivierungsgen 3 (LAG-3), programmierter Zelltodprotein (PD-1) und T-
Zellimmunoglobulin (TIM-3) wurden in den drei Gruppen regulatorische T-Zellen, T-
Helferzellen und zytotoxische T-Zellen separat betrachtet und ausgewertet. Um die 
Expression der Rezeptoren auf tumorinfiltrierenden T-Zellen bewerten zu können 
wurden diese mit Zellen des peripheren Blutes (PBMCs) der entsprechenden 
Patienten und PBMCs von gesunden Spendern verglichen. Es konnte gezeigt werden, 
während fast alle Rezeptoren nur gering exprimiert wurden und dass PD-1 eine 
dominante Rolle im immunsupprimierten Umfeld des Tumors einnimmt. Mit geringer 
oder moderater Expression ist CD137 ein valides Ziel für Immuntherapie.  
Im zweiten Teil wird die Isolation von natürlichen HLA-Liganden von Ovarialtumoren 
beschrieben. Die dabei gefunden Peptide und deren Quellproteine wurden im Kontext 
von gutartigen Ovarien betrachtet. Darüber hinaus wurden Vergleiche mit einer 
Datenbank gezogen, die isolierte HLA-Liganden aus unterschiedlichen gutartigen 
Geweben beinhalten. Durch die Analyse der vergleichenden Ligandenprofile konnten 
Quellproteine bestimmt werden, deren Liganden ausschließlich auf dem HLA von 
Ovarialkarzinomen aber nicht auf dem HLA von anderem Gewebe gefunden wurden. 
Am Ende der Arbeit wurden diese natürlichen tumorexklusiven Liganden dazu genutzt, 
um austherapierte Patientinnen im Heilversuch mit peptidbasierenden Impfungen zu 
behandeln. Hierbei konnte die Behandlungsstrategie zwischen den Patientinnen 
angepasst und verbessert werden. Dabei konnten sowohl HLA Klasse I-als auch HLA 
Klasse II-vermittelte Immunreaktionen nachgewiesen werden. Die Reaktionen wurden 







Located on each side of the uterus, ovaries produce eggs that travel through the 
fallopian tube, where fertilization and the first mitotic cycles may occur. Fertilized 
zygotes then pass into the uterus, implant, and continue prenatal development.  
The ovary consists of three different cell types. The epithelial cells form the outer 
boarder of the ovary, while the stroma cells embed the germ cells and form the 
surrounding tissue. These cells also produce female body hormones estrogen and 
progesterone. Stromal cells also produce the hormones estrogen and progesterone. 
Germ cells are progenitors to the eggs that develop in follicles that will eventually burst, 
allowing the eggs to leave the ovary. Although each of the three ovarian cell types can 
give rise to ovarian cancer, epithelial ovarian cancers (EOC) account for up to 90% of 
all OvCa, and will be the focus of this thesis. EOC can be subdivided into two main 
types. Type I tumors arise from ovarian epithelium and include the germ cell layers. 
They are thought to turn into endometroid, mucinous, clear cell and well-differentiated 
serous tumors, all of which typically show slower clinical progression. Type II tumors 
arise from the fallopian tube and give rise to poorly differentiated serous carcinomas, 
which grow more aggressively and are more prone to metastasis. Both types of EOC 
preferentially metastasize into the peritoneal cavity, where they can affect multiple 
organ systems.   
The International Federation of Gynecology and Obstetrics (FIGO) collaborates with 
world’s leading scientist in obstetrics and gynecology and frequently updates tumor 
staging and optimal treatment approaches. The staging comprises four stages 
considering the spread of disease with the organ of origin, the spread to other organs 
or vessel systems. Early stages of disease are largely symptom free, leading most 
patients to be diagnosed at a later stage (FIGO III or IV).EOCs can also metastasize 
through the lymphatic system via the retroperitoneal lymph nodes that are located 
close to organs and blood vessels [1].  
 
OvCa is a gynecological malignancy and the fifth leading cause of cancer related death 
in women in Germany (Figure 1) [2]. The American Cancer Society reports over 22 
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200 estimated new cases and over 14 000 estimated deaths in the United States in 
2017 [3]. 
 
Figure 1 Comparison of estimated deaths in women in the United States (A) and 
Germany (B) [2]. 
 
The overall 5 year survival rate for all ovarian cancer types is 45%. The tumor type and 
stage, the age at diagnosis and the responsiveness to chemotherapy are crucial 
factors influencing overall survival. The five year relative survival of OvCa patients with 
an early stage diagnosis (FIGO IA and IB) is 92% but around 85% of the patients are 




Figure 2 FIGO staging of ovarian cancer. Stage I tumors are limited to the ovary 
with progression within the ovaries. Stage II tumors can progress into the tubes, 
uterus or pelvic space also including ruptures or metastasis and ascites 
formation. By increasing spread of metastasis into the peritoneum stage III 
tumors are defined. By stage IV distant metastases occur [4]. 
 
Later stage diagnosed patients have a less than 40% five year survival chance, 
emphasizing the importance of early diagnosis methods and routine medical checks. 
Transvaginal sonography can be used to detect even minor morphological changes. 
Additionally abdominal sonography gives insight in the presence of ascites, adhesions 
and other pathological findings in the abdomen. Magnetic resonance imaging (MRI) 
can be used to assess patients in poor condition or with difficult to assess cancers [5], 
however the cost and time involved in obtaining MRI readings makes this technique 
not optimal for routine monitoring. In later staged tumors cancer antigen 125 (CA 125) 








Standard therapy for OvCa patients involves tumor debulking surgery followed by 
platinum-based chemotherapy. Often the ovary is completely removed during surgery 
to increase maximal cytoreduction. The importance of good surgical tumor tissue 
removal should not be underestimated since it was shown that the more tissue was 
removed, the better the overall survival [6]. Carboplatin is used as the standard of care 
chemotherapy since it is less toxic and equally efficient as cisplatin [7]. Platinum-based 
drugs such as cisplatin or carboplatin enter the cell and undergo hydrolysis. The 
reactive platinum molecules bind nucleophilic groups containing oxygen, nitrogen and 
sulfur which can be found in amino acid side chains and the purine bases of RNA and 
DNA. The binding of the DNA is thought to be the mechanism of action since platinum-
DNA adducts interfere with transcription and induce a DNA-damage response resulting 
in tumor cell apoptosis [8, 9].  Chemotherapy is further extended by giving taxane such 
as paclitaxel, which increases overall survival and progression free survival with an 
acceptable safety profile [10]. Paclitaxel is FDA approved for the treatment of ovarian, 
breast and lung cancer. It is a microtubule-stabilizing drug meaning it promotes the 
assembly and prevents the disassembly of microtubules. The constant assembly of 




In general cancer is an age-related disease. OvCa is rare in women younger than 40 
years old, with over half of all OvCas occurring at the age of 63 or older. The highest 
OvCa rates are in post-menopausal women aged 55-64 years. One in 75 women will 
suffer from ovarian cancer [1], making OvCa among the highest probabilities of cancer 
development [12]. Despite the etiology of ovarian cancer remaining largely unknown, 
several risk factors can contribute to the development of OvCa including age, 
nulliparity, infertility, ovulation-inducing drugs. Use of oral contraceptives and 
hysterectomy both significantly reduce the risk of OvCa [13, 14]. Furthermore nutrition 
is also taken into account concerning the risk of developing ovarian cancer. Obesity 






Haematopoietic stems cells in the bone marrow differentiate into common lymphoid 
progenitors, which migrate and colonize the thymus. These developing progenitor cells 
are called thymocytes. Their maturation steps can be identified based on their surface 
marker expression. Most of the T cells developing in the thymus are αβ-T cells. Only a 
small amount of about 5% bear the γδ-TCR. The thymocytes interact with the stromal 
cells of the thymus. During their maturation process thymocytes wander through the 
thymus that consists of the inner medulla and the outer cortex. In the beginning 
thymocytes neither express CD4 nor CD8 and are therefore called double negative 
(DN). 
 
Figure 3 Different stages of T cell development. T cells start as CD4-CD8- double 
negative thymocytes, change the expression profile of different surface markers, 
rearrange α- and β-TCR loci and undergo multiple selections to develop into 
either cytotoxic CD8+ T cell or into CD4+ T cells with either helper or regulatory 
function [16]. 
 
During the DN stage, thymocytes express RAG1/2 and undergo V(D)J recombination 
to produce a functional TCR. For αβ T cells, the TCR β locus rearranges first. To test 
for production of a functional TCR β theβchain pairs with a surrogate TCR α chain to 
form a pre-TCR that complexes with CD3. Following this complex formation, 
thymocytes express survival and proliferation signals, stopβ-chain loci 
rearrangements, and begin rearranging the TCR α locus.  T cells expressing a paired 
TCR αβ also express CD4 and CD8. The majority of CD4+CD8+ double positive 
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cortical thymocytes (DP) die in thymus due to failure to bind peptide-MHC complexes.  
This process, which eliminates useless T cells, is called death by neglect. DP cells with 
TCRs that are capable of binding MHC undergo positive selection in the outer cortex 
of the thymus. During positive selection the TCR weakly binds to MHC-peptide 
complexes presenting self-antigens allowing for signaling through the TCR, leading to 
upregulation of BCL-2 and rescue from default apoptosis. However, too strong 
signaling through the TCR, as would occur for autoreactive specificities, results in a 
negative selection step eliminating thymocytes that migrated into the medulla and 
whose interaction between TCR and self-antigen MHC complex is too strong. During 
the last step of development, one of the co-receptors is downregulated turning 
thymocytes into CD4 or CD8 single positive T cells. About 3% of all thymocytes leave 




Early prediction models of disease progression and survival rates were developed and 
based on factors such as tumor thickness, radial or vertical growth. As the role of the 
immune system in controlling tumor growth has become more appreciated, tumor-
infiltrating lymphocytes and cytokines that influence the tumor microenvironment were 
recently shown as important factors for clinical outcome across a wide range of 
malignancies. Halpern and Schuchter described prognostic models for melanoma and 
the importance of TILs and cytokines as prognostic factors [19]. Further studies have 
shown the importance of intratumoral T cells and their association with progression-
free and overall survival. The potential of TILs was also shown in breast cancer [20], 
renal cell carcinoma [21] and colorectal cancer [22]. In esophageal carcinomas, 
activated, IFN-γ secreting CD8+ T cells were associated with a good prognosis in 
squamous cell and adenocarcinomas [23]. For OvCa, a cohort of epithelial ovarian 
cancer (EOC) patients was analyzed by immunohistochemistry for the presence of 
CD3-positive intratumoral T cells and progression-free and overall survival was 
significantly increased in patients with high amounts of TILs [24]. Collectively, these 
studies suggest the importance of intratumoral lymphocytes in solid tumors and also 







In order to prime naïve T cells, three different signals are required. The first signal 
conveys antigen specificity and is created by binding of the T cell receptor (TCR) to 
the peptide-MHC complex on an antigen presenting cell. Although many cells express 
MHC molecules, dendritic cells are particularly suited to priming naïve T cells. 
Activated dendritic cells also upregulate the chemokine receptor CCR7, allowing them 
to traffic to the draining lymph node and interact with naïve T cells. Naïve T cells that 
recognize their cognate antigen presented on MHC (signal 1) are simultaneously given 
a second signal through the interaction of CD80/CD86 binding to CD28 on T cells as 
a co-stimulatory signal to the TCR-MHC-interaction (Figure 4) [25].  
 
Figure 4 Schematic depiction of interaction between APC and cytotoxic TL (CTL) 
and T-helper cell (TH). The TCR-complex of CTL interacts with the MHC class I 
and TCR-complex of CD4 TH binds MHC class II. TCR engagement is the first 
signal for successful T cell activation. The second signal is created by CD28 that 
binds its ligand CD80/CD86 [26]. 
 
Signal 1 and signal 2 are needed for proper T cell priming. Cytokines such as IL-12 
secreted by the dendritic cell may also influence T cell effector function. The cytokine 
milieu present at the time of naïve T cell priming is called signal 3 and is critically 
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important for formation of CD4 helper T cell subsets. Successful activation of the T cell 
leads to cytokine production and proliferation, and in the case of CD8 T cells, 
acquisition of cytotoxic ability [27]. Effector T cells leave the lymph node and travel to 
inflamed tissues where they can reencounter antigen as peptide-MHC complexes and, 
in the case of CD8 T cells, kill virally infected or transformed cells. Importantly, effector 
CD8 T cells require only TCR:peptide/MHC engagement (signal 1) and can kill their 
targets in a costimulation independent manner. Cytotoxic reaction can be induced by 
perforin and proteases such as granzyme B. Additionally the targeted cell can undergo 
apoptosis caused by the interaction of Fas and Fas-ligand [28].  
 
In case of cancer the immune system can distinguish the myriad of genetic and 
epigenetic alterations that are characteristic to the cancer cells and differentiate them 
from normal tissue counterparts. The quality and amplitude of the immune response 
depends on an interplay of co stimulatory and co-inhibitory signals, called immune 
checkpoints (Fig. 5). Immune checkpoints are critical for preventing autoimmunity by 
inducing self-tolerance and protecting the tissue from taking damage in case of 
infection. Cancerous tissue on the other hand can induce a dysregulated expression 
of immune-checkpoint proteins and therefore manipulate the immune system and 
prevent an anti-cancer immune response [29].  
 
Chemotherapies, radiation and targeted therapies all aim at the malignant cell directly 
and induce tumor cell death. Another approach is cancer immunotherapy, here therapy 
targets the immune system rather than the malignant cell [30]. Immune-based 
therapies for cancer have shown major advances over the past years with adoptive T 
cell transfer, RNA- or peptide-based vaccines and antibodies or small molecules either 




Among the most promising of immunotherapies is the use of antibodies targeting co-
inhibitory or co-stimulatory receptors. With steadily growing numbers of different 
receptors and increased understanding of their effector mechanisms, they became 
attractive targets for cancer immunotherapy. This thesis will focus on tumor necrosis 
factor receptor superfamily member 9 (TNFSR9, 4-1BB, CD137), cytotoxic T 
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lymphocytes associated antigen 4 (CTLA-4), programmed death1 (PD-1), lymphocyte-




Figure 5 T cell response is modulated by numerous activating or inhibiting 
receptors. This interaction is further regulated by various receptor-ligand 
interactions. These responses can occur either upon initiation within the lymph 
node or in the peripheral tissue or tumor tissue. Up to now not all possible ligand 
receptor interactions are fully understood and different combinations might be 
possible. CD28 and CTLA-4 for example share the same ligand but expression 
of receptor occurs either in naive T cells, in case of CD28, or upon T cell 
activation in case of CTLA-4 (modified from [29]). 
 
CD137 also called 4-1BB or tumor necrosis factor receptor superfamily member 9 
(TNFRSF9) is expressed on activated T cells, Tregs, and natural killer (NK) cells. 
CD137 is a costimulatory receptor that belongs to the TNF receptor superfamily [31], 
and has been shown to enhance cytotoxic T cell responses. The treatment of tumor 
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inoculated mice with CD137 mAb lead to eradication of tumor and established memory 
response against the tumor with mice being immune to rechallenge with tumor cells 
[32]. Another study analyzed the effect of agonistic stimulating anti-CD137 antibody 
and the consequence of CD137 knockout in mice. KO mice are more susceptible to 
B16F10 lung metastasis, accompanied with shorter survival compared to similarly 
inoculated control mice. Likewise, treatment with an agonistic stimulatinganti-CD137 
antibody, extends survival in the B16F10 lung metastasis model [33]. The 
immunomodulatory function of CD137 appears to affect naïve T cell priming by 
dendritic cells. The adjuvant role of CD137L was assessed by using the extracellular 
domain of CD137 ligand (CD137L). In combinational of peptide loaded dendritic cells 
and CD137L strongly increased cytotoxic T cell function measured by T-cell 
proliferation, activation and survivals well as IL-2 and IFN-γ production [34]. An anti-
CD137 mAb in a vaccination setting enhances presentation of tumor antigens by 
dendritic cells, leading to reduced tumor recurrence and improved survival [35]. In 
addition anti-CD137 mAb can even reduce the number of tumor-infiltrating Tregs, 
although the mechanism for this Treg reduction is not fully elucidated [36, 37]. 
 
CTLA-4 was the first immune checkpoint to be clinically targeted [38]. It is exclusively 
expressed on T cells where it regulates T cell activation as an antagonist to the CD28 
co-stimulatory receptor. CTLA-4 and CD28 share the same ligands CD80 and CD86. 
Upon engagement of the TCR to the peptide-MHC complex, CD28 strongly amplifies 
TCR signaling subsequently. The expression of CTLA-4 on the T cell surface 
outcompetes the binding to the two ligands because it shows a higher avidity for CD80 
and CD86 than CD28 and therefore dampens the T cell response by delivering 
inhibitory signals [29, 39]. The importance of CTLA-4 in controlling the immune 
response is underscored by the lethality of CTLA-4 knockout in mice causing massive 
lymphoproliferation and fatal multi organ tissue destruction [40]. Despite CTLA-4 being 
expressed on CD8+ T cells, the major function of anti-CTLA-4 immunotherapy appears 
to be depletion of CD4+ intratumoral Tregs, which have higher surface expression of 
CTLA-4 than any other cell in the body [41]. 
 
PD-1 is an inhibitory receptor found on T cells, B cells, dendritic cells and NK cells. 
PD-1 has so far two known ligands, programmed deathligand1/2 (PD-L1/2). PD-L1 is 
found on APCs, some somatic and cancer tissues whereas PD-L2 is selectively 
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expressed on activated monocytes and dendritic cells [42, 43]. The Food and Drug 
Administration (FDA) approved blocking antibodies to the PD-1/PD-L1 pathway, 
pembrolizumab, nivolumab, and atezolizumab. Topalian and colleagues have shown 
that blockade of PD-1 is a potent way of reactivating an immune response in their 
cohort for 18% of the non-small-cell lung carcinoma patients, 25% of the melanoma 
patients, and 27% among patients with renal-cell cancer [44]. Many clinical trials using 
blocking antibodies targeting PD-1 or its ligands and combining it with different types 
of other antibodies or treatments are currently in progress. PD-1 and LAG-3 have been 
shown to work synergistically to prevent autoimmunity in mice [45].  
 
Lymphocyte activation gene-3 (Lag-3) is up regulated on both CD4+ and CD8+ T cells. 
Lag-3 deficient mice revealed Lag-3 to be a negative regulator of T cell expansion. 
Despite LAG-3 and CD4 sharing less than 20% amino acid sequence homology, the 
structure of Lag-3 is quiet similar to CD4 [46]. Thus Lag-3 likewise to CD4 binds MHC 
class II and acts as a negative competitor [47]. Lag-3 is also expressed by regulatory 
T cells. Studies have shown that modulation of LAG-3 can enhance or abrogate Treg 
activity [48].  
 
T cell immunoglobulin-3 (Tim-3) is a cell surface molecule expressed on IFN-γ 
producing CD4+ T helper cells, CD8+ cytotoxic T cells, Tregs and innate immune cells 
such as dendritic cells, natural killer cells and monocytes [42]. Tim-3 functions as a 
negative regulator of type 1 immunity. Mice treated with anti-TIM-3-antibody have 
exacerbated experimental autoimmune encephalomyelitis, a mouse model of multiple 
sclerosis [49]. 
 
Being the only cell type in the human organism capable of producing antibodies B cells 
play an important role in creating an immune response. Additionally they serve as 
antigen presenting cells and express co-inhibitory and co-stimulatory receptors on the 
cell surface. Furthermore B cells can secret cytokines overall having multiple ways to 
influence the immune response [50]. 
 
B cells have been shown to be reasonable prognostic factors in cancer patients such 
as node-negative breast cancer [51] metastatic melanoma [52]and advanced ovarian 
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cancer [53]. Within these cancers the amount of infiltrating B cells positively correlated 
with progression-free and overall survival. 
In addition to that a regulatory B cell (Bregs) phenotype has been described, remaining 
yet to be fully understood [50]. They have been reported to be able to suppress IFN-γ 
and TNF-α secretion by T cells and their proliferation. CD19(+)CD24(hi)CD38(hi) B 
cells were able to inhibit naïve T cell differentiation into TH1 and TH17 cells and 
mediate Treg-properties [54]. These properties have been shown to be induced 
through immunosuppressive cytokines such as IL-10 and TGF-β and induction of 
FoxP3 and CTLA-4 expression [55]. 
 
Besides the known high impact of the adaptive immune system there is increased 
evidence of tumor surveillance by natural killer cells (NK cells). Early studies have 
shown NK cells are able to discriminate tumor cells from normal tissue and eradicate 
the tumor. Tumor cells may lose expression of MHC molecules, which can be detected 
by NK cells. Furthermore, tumor cells upregulate the stress ligands MICA/B, which can 
be recognized by activating NK receptors, inducing NK mediated killing. A rechallenge 
following a first sensitization of NK cells leads to persistent rejection of tumor [56]. 
Besides that depletion of NK cells in mice through NK1.1 binding antibodies lead to a 
higher susceptibility to B16 melanoma and increasing mortality of NK cell depleted 
mice. However depletion did not influence distribution of other lymphocyte subsets 
[57]. NK cells control cancer either by direct interacting with tumor cells or augmenting 
the activities of other tumor cells in the tumor microenvironment. NK cells may directly 
release perforin and granzyme, leading to tumor cell lysis [58]. Furthermore NK cells 
can induce tumor cell death through death receptor-mediated pathways such as FasL 




Another problem than overcoming the immunosuppressive tumor microenvironment is 
to stimulate T cells. A major focus in current research are cytotoxic T cells capable of 
directly eradicating tumor cells. Antigen processing, presentation and isolation are key 
points in the selection process of vaccination peptides.   
1.8 Major histocompatibility complex 
 
The MHC molecules present peptide fragments derived from pathogens or mutated 
proteins on the cell surface. In the consequence the infected or mutated cells are killed, 
macrophages and B cell are activated. B cells subsequently produce antibodies that 
are eliminating or neutralizing extracellular pathogens.   
The MHC is polygenic meaning there are several different MHC class I and MHC class 
II genes that create a set of MHC molecules with different ranges of peptide-binding 
specificities in each individual.  Secondly MHC molecules are polymorphic meaning 
there are multiple variants of each gene within the population as a whole. The MHC is 
located on chromosome 6 in humans and contains more than 200 genes whereas the 
genes for the β2-microglubulin and the invariant chain are located on chromosomes 15 
and chromosome 5. The genes for the α-chain of MHC class I and the α and β chain 
for MHC class II are linked within the gene complex. In humans the MHC is called 
human leukocyte antigen (HLA) since they were first discovered as differences in 
leukocytes between individuals.  
 
Figure 6 Gene structure of MHC class I and MHC class II on human 
chromosome 6. There are three HLA class I genes (HLA-A, -B and -C) as well as 
three pairs of MHC class II α and β chain genes (HLA-DR, -DP, -DQ) (adapted 
from [62]). 
The combination of MHC alleles found on a single chromosome is called MHC 
haplotype with MHC genes being codominantly expressed with both HLA alleles of 
each locus to produce molecules that present peptides at the cell surface. The 
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treatment of cells with interferons-α, -β, -γ leads to an upregulation of MHC-α chain 
and β2-microglubulin genes as well as genes encoding the proteasome, tapasin and 
TAP.  
 
Peptides bind MHC class I through specific anchor residues with the sidechains of 
these residues anchoring binding pockets along the peptide binding groove of the MHC 
class I molecule. Each MHC class I molecule has a specific preferred sequence motif 
allowing the prediction of potential MHC binders from a given protein sequence. MHC 
class II also has different allelic variants that have a certain preferred peptide sequence 
motif. In contrast to MHC class I the peptide-binding groove is bigger allowing the 
binding of longer peptides and an overall greater flexibility in peptide binding. 
Concluding it is more difficult to predict MHC class II binding peptides [62]. 
 
The process of antigen presentation shows the current state of the cell. Here antigens 
are presented at the cell surface to be recognized by the immune system. These 
peptides are either presented by major histocompatibility complex class I (MHC I) 
molecules by all nucleated cells to CD8+ T lymphocytes. Alternatively the peptides can 
be presented by major histocompatibility complex class II (MHC II) to CD4+ T 
lymphocytes by antigen presenting cells (APC) such as dendritic cells (DC), 
macrophages and B lymphocytes. In general peptides presented by MHC I are derived 
from intracellular peptides. Peptides presented on MHC II are derived from source 
proteins from the extracellular space.  
 
Vaccinating and immunizing patients with peptide-based vaccines can be achieved in 
two ways: either Peptides can be predicted with bioinformatitional tools such as 
SYFPEITHI or NetMHCpan-3.0. These tools predict the binding probability 
(SYFPEITHI) or binding affinity (NetMHCpan-3.0) of a peptide to a certain HLA of 
interest. Predicted peptides sometimes fail to induce proper immune responses, 
especially if the source protein is low abundant or the HLA of interest has a natural low 
affinity to its peptides in general.  
 
Therefore isolating peptides via liquid chromatography-coupled mass spectrometry is 
a more suitable approach to identify peptides that can be used as vaccination peptides. 
These peptides are naturally presented HLA ligands and since they are isolated from 
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The following peptides were shown to be OvCa associated in preliminary work of our 
lab. Additionally they were put in context for tumor development and progression in 
other tumor entities. 
  
Mucin16 (MUC16) also called cancer antigen125 (CA125) is a commonly used ovarian 
cancer serum marker. It is a very large type-1 transmembrane mucin with about 22152 
amino acids [63, 64]. First of all Muc16 can be used for early detection of OvCa, 
additionally it can be used to monitor the response the response to OvCa treatment 
and control for tumor recurrence. Despite its important role in OvCa MUC16 is 
overexpressed in breast, pancreatic and colorectal cancer [65] and being mutated in 
other tumor types as well [66].  
 
The cellular retinoic acid-binding proteins-1 and-2 regulate the access of retinoic acid 
to the nuclear retinoic acid receptors. It was early described that CRABP is present in 
tissue of patients with large bowl cancer [67]. CRABP 2 seems to be involved in the 
inhibition of tumor growth since the activation of retinoic acid receptor with retinoic acid 
leads to expression of ant proliferative genes [68]. Yet its complete function in 
tumorigenesis still remains to be fully understood.  
 
Indoleamine 2,3-dioxigenase 1 (IDO1)is the main enzyme that catalyzes the first rate 
limiting step  in the metabolic cascade that converts the essential amino acid L-
tryptophan into L-kynurenine. IDO-1 is constitutively expressed by tumor tissue cells. 
The metabolic pathway has been shown to establish peripheral tolerance and creating 
a tumor suppressive microenvironment. This feature makes it an attractive target for 
cancer immunotherapy [69, 70].  
Matrix metalloproteinase 11 (MMP11 or stromelysin-3) has been reported to be 
involved in in the development and progression of a variety of malignancies. In general 
matrix metalloproteases are key regulators in the metabolism of connective tissue 
matrices. MMP11 exerts collagenolytic functions. In cancer they can promote 
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oncogenic transformation and angiogenesis supporting tumor growth and metastasis 
[71]. 
 
Human pituitary tumor-transforming gene (PTTG or securin) is a proto-oncogene in the 
development invasion and metastasis in a variety of different tumor types including 
OvCa. Its overexpression induces cellular transformation and tumor development in 
mice. Furthermore PTTG overexpression correlates with worse differentiation in OvCa 
[72].  Short interfering RNAs (siRNA) reduced expression of PTTG mRNA and protein 
and subsequently to a 50% reduction in cell proliferation. Mice constitutively 
expressing siRNA against PTTG lead to a reduction in tumor development and tumor 
growth [73]. In humans PTTG expression correlated with invasiveness and vessel 
density [74, 75]. 
 
Eyes absent homolog 2 (EYA2) functions as a protein phosphatase and transcriptional 
coactivator for SIX1. SIX1 has been shown to be dependent on EYA2 expression to 
mediate epithelial-mesenchymal transition (EMT) and induction of cancer stem cell 
formation (CSCs). In breast cancer patients EYA2/SIX1 expression correlated with 
shortened time of relapse, metastasis and overall survival. Whereas EYA2/SIX1 are 
expressed only in a few adult tissues making them attractive targets for cancer therapy 
[76].   
 
Galectin-1 (LGALS-1) belongs to the family of galectin proteins binding galactoside. 
LGALS1 is highly expressed in various tumors and their oncogenic processes. 
Galectin-1 is highly expressed in colon [77], glioma [78], breast [79], lung [80], head 
and neck [81], ovarian [82] and prostate carcinoma [83] being associated with 
metastasis and tumor growth [84].   
 
The folate receptor α (FOLR1) transports folate into the cells which is needed in cell 
metabolism. Overexpression of FOLR1 is associated with increased tumor growth by 
increased folate uptake. In an attempt to target FOLR1 antibodies and conjugates have 
been developed in order to treat OvCa and lung cancer whereas FOLR1 is also 




KLK10 also called kallikrein-related peptidase 10 is one of 15 highly conserved serine 
proteases. They are potential biomarkers of prostate, breast, ovarian, gastrointestinal, 
head and neck, lung and brain cancer. Most famous kallikrein is the prostate specific 
antigen (PSA or KLK3) that is used as a biomarker for prostate cancer [86].  
 
The transmembrane protein 158 (TMEM158) was overexpressed in OvCa and a 
knockdown of TMEM158 RNA leads to significantly inhibition of cell proliferation. This 
inhibition may be caused by an increased G1-phase arrest due to its interaction with 
Ras that induces senescence. Silencing of  
TMEM158 inhibited cell adhesion, cell invasion as well as tumorigenicity [87].  
 
Mesothelin and MUC16 were found to be upregulated in the infiltrating compartment 
of pancreatic ductal adenocarcinoma impaling their involvement in migration and 
metastasis [88].  
 
Tumor exclusive ligands are seemingly the best to use in cancer immunotherapy. The 
ideal application consists of a selection of peptides for each individual separately. To 
set up such an individualized therapy a warehouse of preselected peptides is needed.  
The warehouse idea comprises the possibility of having a big number of peptides 
available for cancer patient treatment. Each peptide is restricted by a certain HLA. 
Depending on the patients HLA up to 10 peptides are chosen, selecting the most 
immunogenic and best suiting ones for each patient, combining them into a cocktail. 
With this off-the-shelf use of peptides maximum flexibility is granted allowing individual 
and ideal therapy.  
 
In order to establish the warehouse properly, compassionate use of peptides was not 
only dependent on HLA-genotype of each patient but also was a MS-analysis 
performed. Peptide lists of patients were searched for warehouse peptides. A cocktail 







Adjuvants in cancer immunotherapy can give an additional boost to the immune 
system, priming an immunereaction and support the effectivity of the applied drug 
drastically.  The ideal adjuvant provides optimal availability of the antigen by regulating 
its persistence, location, concentration and presentation [89].  
Incomplete Freund’s adjuvant (IFA), does not contain heat-killed Mycobacteria 
tuberculosis to avoid acute granulomatous lesions at the site of vaccination. IFA is a 
water-in-oil emulsion and is characterized by its depot effect and slow release of 
emulsified antigen inducing strong cellular and humoral immune reaction.  Especially 
the vaccination with long peptides induced cytokine production and efficient T cell 
priming through DCs [90]. Accordingly the persistent activation and attraction of T cells 
prevent them from entering the tumor site and subsequently resulting in T cell 
exhaustion and Fas/Fas-L mediated cell death [91]. 
 
Aluminum-based adjuvants such as aluminum hydroxid (Alhydrogel™) and aluminum 
phosphate (Adjut-phos™) are used in virus vaccines against influenza, tetanus, 
diphtheria, pertussis, poliomyelitis and HPV [92]. Aluminum-based adjuvants are 
characterized by a depot effect. It has been reported that aluminum-based adjuvants 
induce intense antibody production [93].  
 
Micro- and nanoparticles have advantageous features such as protection of their cargo 
against degrading factors such as serum/tissue peptidases or proteases increasing the 
half-life of their cargo. Furthermore these particles can be engineered by charge, rigidy, 
size or added ligands on particle surface to target certain tissues types or organs [89] 
As vaccines changed from vaccinating with attenuated or dead pathogens towards 
recombinant artificial subunits scientists discovered the family of highly conserved 
pattern recognition receptors (PRR) called Toll-like receptors (TLR) [94] Since then 
more PRRs have been discovered such as NOD-like receptors (NLR), C-type lectin 
receptors and retinoic acid inducible gene (RIG)-1-like receptors (RLR) and with this 
adjuvants have been developed to additionally stimulate the immune system and 
promote effectiveness of vaccines[95-97]. TLR2 can be engaged by bacterial 
lipopeptides or palmitic acid. Stimulation of TLR2 lead to DC maturation [98]and up-
regulation of co-stimulatory signals (such as CD80 and MHC class II) [99], B-cell 
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activation [100], enhanced T-cell response and pro-inflammatory cytokine secretion 
such as IFN-γ or TNF-α [101-103]. 
 
TLR3 agonists such as double-stranded RNA or the synthetic analog polyinosine-
polycytidylic acid (poly I:C) can engage TLR3 in in the endosome DCs, macrophages 
and on the surface of epithelial cells [104]. It can induce the production of inflammatory 
cytokines, type 1 interferons followed by upregulation of co-stimulatory signals [103]. 
Despite its short half-life poly I:C has been shown to enhance cross-presentation by 
DC to CD8+ T cells  [102].  
 
TLR4 is expressed on the surface of DCs, macrophages, fibroblasts and epithelial 
cells.  TLR4 activation strongly promotes TH1 response [105]. Since LPS is potentially 
dangerous to the patient it has been replaced with less toxic synthetic derivates such 
as monophosphory lipid A (MPLA) which has been tested in combination with other 
antigens in clinical trials for melanoma [106], lung [107] and prostate cancer [108].  
 
TLR7 and TLR8 recognize single stranded RNA (ssRNA) in the endosomal 
compartment.TLR7/8 are expressed by antigen presenting cells. It has been shown 
that signaling from TLR7/8 gets DCs to migrate from the skin to the lymphnode 
presenting antigens to CTLs and T helper cells. Imiquimod is an imidazoquinoline 
amine and known as a potent immune response modifier inducing anti-viral and anti-
tumor activity. Imiquimod was FDA approved to treat basal cell carcinoma and genital 
warts. It stimulates the production and release of cytokines such as interferon-α (IFN-
α), interleukin-6 (IL-6) and tumor-necrosis factor-α (TNF-α9: Cytokine production was 
induce after topical application to the skin of hairless mice. Additionally it was shown 
that Imiquimod activates macrophages to secrete cytokines. It was applied 
epicutanously on the vaccination site. Additionally there have been clinical studies 
using Imiquimod supporting their vaccines targeting melanoma [109], prostate cancer 
[110], chronic myeloid leukemia [111] and vulva intraepithelial neoplasia [112]. 







Peptide-based anti-cancer vaccines are promising ways of treating different cancer 
entities. The manifold advantages of peptide vaccines are they are relatively easy to 
synthesize, relatively stable in storage and show no oncogenic potential. Nevertheless 
their application is complicated and numerous parameters have to be set. Thus until 
now peptides have shown only poor immunogenicity. The choice of antigen the 
peptides are derived from and the suppressive microenvironment are further hurdles 
to overcome in order to successfully establish an anti-tumor vaccine. Antigenic HLA 
ligands are derived from tumor associated antigens (TAA) or tumor-specific antigens 
(TSA) [113, 114]. TAAs are found on tumor and on benign tissue but are generally 
found in higher amounts on the benign tissue. TSAs are exclusively found on tumor 
cells and caused by viral infection or genetic mutations. TAAs can be divided into 
differentiation antigens, cancer/ testis antigens, and overexpressed antigens. 
Differentiated antigens such as melanoma Ag recognized by T cells (MART-1)/Melan 
A, gp100, tyrosinase, tyrosinase-related protein (TRP-1) and TRP-2 are used to treat 
melanoma. Cancer/testis antigens share expression between tumor and germ line 
cells. Theses antigens do not induce an immune response against benign testis cells 
since these do not express MHC making cancer testis antigens attractive targets in 
cancer immunotherapy. Well studied examples of cancer/testis antigens are MAGE-1 
and NY-ESO-1. HER-2 is a classical representative of the overexpressed tumor 
antigens. HER-2 is expressed in higher amounts during embryonal development but 
expressed in low amounts on normal tissue in adults whereas HER-2 is highly 
overexpressed in breast, ovarian and non-small-cell-lung cancer [115]. 
Montanide™ ISA-51 is a mineral oil-based emulsifier that stays at the injection site and 
is progressively eliminated by immune cells such as macrophages. It is metabolized 
into its compounds of fatty acids, triglycerides, phospholipids and sterols [116]. The 
degradation process is long lasting. It was shown that only 30% of the mineral oil is 
degraded within the first month which was found out by using radioactive tracers [117]. 
Montanide™ ISA-720 is based on plant oil, thus easier to degrade by but still offering 







Ovarian cancer patients are often diagnosed at later stage of disease since disease 
progression remains largely symptom free. Post-menopausal monitoring for malignant 
transformation is difficult and elaborate. The blood level of Muc16 also called cancer 
antigen 125 (CA125) can be used as a tumor marker to discover and monitor disease 
occurrence and progression. Nevertheless, with low overall 5 year survival of OvCa 
patients and a high tumor recurrence rate there is still an urgent need for optimized 
treatment. Recent advances in cancer immunotherapy utilized immune checkpoint 
blocking antibodies. The blocking antibodies inhibited the inhibitory receptors 
expressed by effector T cells supporting them to overcome immunosuppressive tumor 
microenvironment. A vast number of immune checkpoint inhibitors have been identified 
and tremendous efforts were made to create blocking antibodies. Best choice of 
antibody can be crucial for therapy success and reduction of side effects. To find the 
ideal target for checkpoint inhibitor blocking antibodies broad analysis of coinhibitory 
and costimulatory receptors are needed. Therefore this thesis will focus on the analysis 
of LAG-3, CTLA-4, PD-1, TIM-3 and CD137 expression on CD4+ regulatory T cells, 
CD4+ non-regulatory T cells and CD8+ cytotoxic T cells. These three T cell subsets 
are key players in the regulation and mediation of tumor growth, progression and 
eradication.  
A major focus lies on the stimulation of cytotoxic T cells because of their ability to 
directly kill tumor cells. Stimulation of CTLs requires presentation of short 8-12 amino 
acids long peptides presented on the HLA as a first signal. The immune peptidome 
landscape of OvCa tissue will be surveyed by liquid chromatography coupled mass 
spectrometry. To distinguish OvCa related peptides and their respective source 
proteins from peptides presented by benign tissue comparative profiling will be used. 
With the so identified peptide sequences we are aiming to treat fully resected OvCa 
patients. Patients will receive multiple vaccinations. Supporting peptide vaccination 
different adjuvants are tested in order to improve therapy efficiency.  Response against 






To compare the changes in expression profiles, blood samples were taken of each 
patient before tumor-debulking surgery and fresh tumor tissue was collected as part 
from the overall tumor mass. Tissue was mechanically minced with a scalpel into 
pieces of around 1 mm3. Depending on the quality of the tissue, fatty adjacent benign 
tissue was removed as far as differentiable. The tumor tissue was enzymatically 
digested with collagenase IV to achieve a single cell suspension. 
PBMCs were isolated by grade density centrifugation and stained along with the single 
cell suspension. Therefore, cell suspensions were layered onto Ficoll-Hypaque and 
centrifuged at 2000 rpm for 20 min without break. The cell layer containing both 
lymphocytes and monocytes was taken and further analyzed. Prelimenary experiments 
have shown high amounts of debris in flow cytometry analysis. Ficoll isolation of cells 
reduced debris and unspecific background staining.   
Samples were analyzed via flow cytometry with a BD Fortessa. Co-receptor expression 
was compared between lymphocytes from PBMCs and TILs analyzing separately 
CD4+ non-Tregs, CD4+ Tregs and CD8+ cytotoxic T cells.  
Statistical analysis was performed using Graphpad Prism software (version 7.03). 
Results were tested for normality by the D'Agostino & Pearson normality test and 
depending on the distribution either unpaired student t-test in case of normal 
distribution of data or Mann Whitney test in case of non-parametric data were used. 
Staining with the first panel assesses the landscape of co-inhibitory and co-stimulatory 
receptors. It further allows a differentiation of CD4 and CD8 T cells and shows the 







Table 1 Antibody panel staining for coreceptors on PBMCs and TILs of OvCa. 
The first column contains the specificities followed by the bound fluorochrome 
and the antibody clone.  
specificity fluorochrome clone company purpose/ 
population 
CCR7 Brilliant Violet 421 G043H7 BioLegend memory 
phenotype 





CD8 Brilliant Violet 605 RPA-T8 BioLegend CTL 
CD4 Brilliant Violet 711 OKT4 BioLegend TH/Treg 
CD45RO Brilliant violet 650 UCHL1 BioLegend memory 
phenotype 
CD45 PerCP HI30 BioLegend lymphocyte  




CD25 PeCy7 M-A251 BDbioscience
s 
Treg-gating 
PD-1 APC Cy7 EH12.2H7 BioLegend checkpoint 
inhibitor 
TIM-3 APC F38-2E2 BioLegend checkpoint 
inhibitor 
CD137 Alexa Fluor 700 4B4-1 BioLegend checkpoint 
inhibitor 





The second panel was used to get a better overview of cellular composition of TILs. 
More specifically CD19 was used as a marker for B-cells, NKp46 as a marker for NK 




Table 2 Antibody panel staining for lymphocyte subsets and tumor cells. 
specificity fluorochrome clone company purpose / 
population 
CD3 PeCy7 UCHT1 BioLegend T cell 
CD45 PerCP HI30 BioLegend lymphocyte 
CD19 Pacific Blue HIB19 BioLegend B cell 
NKp46 FITC L9E2 BioLegend NK cell 
EpCAM APC  MiltenyiBiotec tumor cell marker 






For the staining of coinhibitory and costimulatory receptors isotype controls with the 
respective fluorochrome were used to exclude the background staining. 




FITC-IgG1 MOPC-21 ENZO Life Sciences 
PE-IgG2a MOPC-173 BioLegend 
APC/Cy7-IgG1 MOPC-21 BioLegend 
APC-IgG1 MOPC-21 BioLegend 







Analytical balance      Sartorius 
Cell culture hood      Technoflow,  
Integra Biosciences 
Centrifuge       Eppendorf 
Cryo freezing container     Nalgene 
ELISPOT reader Immunospot    cellular Technologies Ltd 
        (Software Immunospot 3.2) 
Flow cytometer FACS-Fortessa     Becton Dickinson 
(incl. software FACS DIVA) 
Incubator for cell cultures     Heraeus 
(Heraeus BB6220 CU) 
Light microscope      Zeiss 
Mass Spectrometer (LTQ Orbitrap XL)   Thermo scientific 
Neubauer counting chamber, depth 0.1mm  LO-Laboroptik 
Peristaltic pump (LKB P-1)    GE-healthcare 
Pipettes       Abimed 
Potter glass tube      novodirect 
Precision balance      Sartorius 
Proteome discoverer 1.3     Thermo scientific 
Speed vac vaccum concentrator    Bachofer 
Spinning wheel      Bachofer 




50 ml reagent reservoir      Corning 
6-well and 24-well plates     Greiner bio-one 
96-well plates (F-bottom)     Corning 
96-well plates (U-bottom)     Corning 
Cell culture flask (75 cm2, 175 cm2)   Greiner bio-one 
Cryotubes (2 ml)      Greiner bio-one 
ELISPOT plates, 96 well (MSHAN4B)   Millipore 
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FACS tubes (5ml)      Becton Dickinson 
NMWL 10,000 ultrafiltration tube (Amicon Ultra-15) Millipore 
NMWL 10,000 ultrafiltration tube (Amicon Ultra-4) Millipore 
Petri dish       Greiner bio-one 
Safe-lock tubes (0.5 ml, 1.5 ml, 2 ml)   Eppendorf 
Surgical disposable scalpel    Braun 
Tubes (15 ml, 50 ml)     Greiner bio-one 




2-propanol (isopropanol)     Merck 
4-(2-hydroxyethyl-1-piperazineethanesulfonic acid  Gibco (Life technologies) 
(HEPES) 
Acetonitrile (MS-grade)     Thermo scientific 
Alkaline phosphatase (avidine conjugated)  Sigma-Aldrich 
Anti-human HLA class I, mouse, clone W6/32  in house production by 
        C. Falkenburger 
Anti-human HLA-DR, -DP and –DQ, mouse,   in house production by 
Clone L243       C. Falkenburger 
Anti-human HLA-DR, -DP and –DQ, mouse,   in house production by 
Clone Tü-39       C. Falkenburger 
BCIP/NBT tablet      Sigma-Aldrich 
Bovine Serum Albumin (BSA)    Sigma-Aldrich 
CHAPS       AppliChem 
CNBR-activated sepharose    GE-Healthcare 
Collagenase Type IV     Gibco 
Complete protease inhibitor tablet   Roche 
Dimethyl sulfoxide (DMSO)    WAK-Chemie 
DMEM        Gibco 
(Dulbecco´s Modified Eagle Medium) 
DNase       Roche 
Ethanol       SAV LP 
Ethylenediaminetetraacetic acid (EDTA)  Roth 
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Ficoll (Biocoll)      Millipore 
Human IL-2       R&D Systems 
IMDM 
(Icove`s Modified Dulbecco`s Medium)   Lonza 
Ionomycin        Sigma-Aldrich 
Pen/Strep        Sigma-Aldrich 
Phosphate buffered saline (PBS)    Gibco (Life technologies) 
Phytohaemagglutinin (PHA)    Sigma-Aldrich 
RPMI        Gibco (Life Technologies) 
Trifluoroacetic acid (TFA)     Apllied biosystems 
Trypan Blue       Gibco (Life Technologies) 
Tween 20       Merck 




Coupling buffer      0.1 M NaHCO3, 0.5 M NaCL in ddH2O  
DMEM medium     1% Pen/Strep, 10% FCS in DMEM 
Desalting solution     1% (v/v) formic acid in H2O  
(MS-Grade) 
Elution solution     1% (v/v) formic acid, 50% (v/v)  
acetonitrile in H2O (MS-Grade) 
FACS buffer      0.01% NaN3, 2 mM EDTA,  
2% FCS in PBS 
Freezing medium     10% DMSO in FCS 
Loading solvent      0.05% TFA, 1% acetonitrile  
in H2O (MS-Grade) 
PBS-BSA      0.5% BSA in PBS 
PBS-Tween      0.05% Tween in PBS 
Solulibisation buffer     1 tablet complete protease inhibitor 
       400 mg CHAPS in 33 ml PBS 
Solvent B      0.05% TFA, 80% acetonitrile  
in H2O (MS-Grade) 
T Cell Medium     10% human plasma in IMDM 
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Thawing medium     3 µg/ml DNase, 1% Pen/Strep,  




To isolate natural presented ligands, snap frozen tumor tissue is mechanically and 
chemically degraded with a scalpel and solubilization buffer. The sample-buffer 
solution is then transferred to a potter tube and degraded with a potter. After another 
incubation step of pottered tissue, the suspension was sonicated with ultrasound to 
lyse cellular membranes. The lysate was incubated once more and centrifuged to 
separate MHC-complexes in suspension from cellular debris and tissue fragments. 
Followed by immunoprecipitation of peptide-MHC complexes using the W6/32 [118] 
capture-antibody for HLA-class I molecules and a combination of the L243 [119]  and 
Tue-39 [120] capture antibodies for HLA-class II that were coupled to an activated 
CNBr-sepharose matrix. The peptides were then eluted by mild-acidic elution using 
0.2% trifluoroaceticacid (TFA) and analyzed by liquid-chromatography coupled mass 
spectrometry. Peptide spectra were searched against the human proteome 
(Uniprot/Swissprot 130927) using Seaquest search engine with a precursor mass of 5 
ppm and a fragment mass tolerance of 0.02 Da. False discovery rate (FDR) of peptide 
spectrum hits was calculated using percolator.  
The identified peptides with a FDR < 5%  were then further processed and evaluated 
for their capability to bind to an HLA allotype of each patient/donor. Peptides with a 
binding score of ≥ 50% of the maximal score of SYFPEITHI and a binding affinity of 
≤500 nM on NetMHC were defined as binders. Peptides were filtered in length of 8-12 
amino acids length for HLA class I and 12 to 25 for HLA class II.  
In order to determine tumor exclusiveness of cancer proteins a waterfall plot is 
generated, comparing benign ovary to OvCa source proteins and respective peptide 
lists that contain ligandomat determined binders of each patients HLA type. The source 
proteins that were determined to be tumor exclusive were filtered and corresponding 







Peptides were selected from a warehouse (table 12) containing HLA-matched tumor 
exclusive peptides. The author of this thesis contributed sequences to this warehouse. 
All OvCa IDs numbered 99 or higher are contributions of the author of this thesis while 
the others are preliminary work by Dr. Heiko Schuster and Dr. Janet Peper. The 
warehouse contains the information of source protein, peptide sequence and HLA 
restriction [121]. HLA typings of all three patients vaccinated are shown in the 
supplemental data (table 8). Furthermore peptides are rated depending on frequency 
of presentation on different OvCa samples and immunogenicity in T cell primings using 
artificial antigen presenting cells (aAPCs). The immunogenicity was assessed via T 
cell priming with aAPCs in healthy donors. Artificial antigen presenting cells are 
microbeads that have MHC:peptide complexes covalently bound on their surface. For 
the T cell priming CD8+ T cells are isolated from whole blood donations. Subsequently 
they were alternatingly stimulated every 3 to 4 days with IL-2 and aAPCs. The readout 
was done with tetramer staining and ICS. The immunogenicity testing was performed 
by Dr. Janet Peper and the warehouse was set up in cooperation with Dr. Heiko 
Schuster. 
Patients chosen for compassionate use therapy were fully resected (R0) and tumor 




The effectiveness of peptide vaccination was assessed by a twelve day stimulation of 
PBMCs isolated right before every injection of vaccination.  
Therefore, PBMCs were isolated as described in chapter 1 and cryopreserved. The 
frozen cells are thawed quickly using DNase-containing thawing medium. After 
transferring cells into T-cell medium with 5% human serum they are rested overnight. 
The following day cells were pool-stimulated with target peptides and an HLA-matched 
negative control viral peptide at a final concentration of 1 µg/ml for HLA-class I peptides 
and 3 µg/ml for HLA class II peptides.  At day three, six and eight cells were stimulated 
with 20 U/ml IL-2. After a medium exchange on day 10 the IFN-γ capture antibody 
coated ELISpot plate was loaded on day 13 and stained on day 14. 500,000 cells were 
40 
 
seeded per well and re-stimulated again with peptide, or as additional controls with 








To analyze the immunological landscape of OvCa, TILs and PBMCs of each patient 
were freshly isolated the day of tumor debulking surgery. The amount of receptor 
positive cells was based on CD4 and CD8 expression.  CD4+ T cells were subdivided 
into Tregs and non-Tregs via the CD25+ CD127low staining.  
As an additional control 10 volunteer women (HD) aged 52-59 years donated blood for 
PBMC analysis in order to determine changes in the expression pattern of receptors 
that might be altered on PBMCs of patients. 
 
 
Figure 7 Differences in amounts of CD8+ and CD4+ Tregs and non-Tregs. Shown 
are cells from 10 healthy donors (HD) and 17 OvCas. Different subsets are shown 
as part of CD45. Each group was homogenous within itself and did not differ 
significantly between the three groups regardless if Tregs, non-Tregs or CTL.  
Treg groups do not differ and form very homogenous cluster in healthy donors (HD), 
and PBMCs as well as Tregs of patients. The spread in abundance of CD4+ non-Tregs 
and CD8+ T cells is wider but there are no drastic differences between different 
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samples. In addition to that, no significant difference was observed between the 





Figure 8 Comparison of CD4+ Tregs expressing CD137. Shown are results of 10 
healthy donors (HD) and 17 OvCas. HD and OvCa PBMCs did not differ but there 
was a significant difference between PBMCs and TILs.  
TILs from half of the patients had moderate amounts of regulatory T cells expressing 
CD137. Thus the other half of patients were characterized by low amounts or no Tregs 
expressing CD137. In healthy donors no Tregs expressed CD137. The expression of 
immune checkpoint inhibitors on Tregs remains broadly unknown. Adoptively 
transferred CD137+ Tregs in a lymphoma mouse model had significant impact on 
tumor progression. CD137+ Tregs suppressed proliferation of effector cells while Tregs 
persisted after the transfer in the host mice. The Tregs were inhibited tumor rejection. 





Figure 9 Comparison of CD4+ Tregs expressing CTLA-4. Shown are 10 healthy 
donors (HD) and 17 OvCas. HD did neither differ from OvCa PBMCs nor from 
TILs. No CD4+ Tregs were found CTLA-4 positive. 
CTLA-4 is needed in Tregs to function as suppressor [123]. The blockade of PD-1 and 
CTLA-4 in vitro using blocking antibody followed by a transfer of treated cells enhanced 
effector infiltration and activation. However it was reported that the blockade ultimately 
affected Tregs inhibiting them in their suppressor function [124]. Comparing CTLA-4 
among regulatory T cells of PBMCs and TILs, neither of the two groups were 
expressing CTLA-4. Only one patient was found to be positive in around two percent 




Figure 10 Comparison of CD4+ Tregs expressing LAG-3. Shown are 10 healthy 
donors (HD) and 17 OvCas. HD remain completely negative for LAG-3 
expression. OvCa PBMCs and TILs were mostly negative for LAG-3 expression.   
Equal to the expression of CTLA-4 samples were broadly negative for the expression 
of LAG-3 in Tregs derived from PBMCs and TILs, whereas three patients had between 
5 to 10% of positive Tregs among their PBMCs. Those three patients were among the 
5 samples with 5 to 10% of positive Tregs of TILs. One outlier was recorded to even 
have more than 30% of positive Tregs in her isolated TILs. At this point little is known 
about the role of LAG-3 expression by Tregs in the context of tumor progression. A 
study has shown that LAG-3 expression by Tregs are able to suppress the production 
of autoantibodies in a lupus mouse model [125]. Therefore LAG-3 seems to have a 




Figure 11 Comparison of CD4+ Tregs expressing TIM-3. Shown are 10 healthy 
donors (HD) and 17 OvCas. HD did not differ from OvCa PBMCs. TILs trended 
towards increased amounts but did not differ significantly from PBMCs. 
PBMCs from HD were negative for the expression of TIM-3. One sample was an outlier 
with around 2% of positive cells. There were two outliers in PBMCs of OvCa samples. 
The other OvCa PBMC samples were negative for the expression of TIM-3. The 
expression of TIM-3 was more heterogenous in OvCa TILs.  
TIM-3 expressing Tregs have been shown to be T cells with the most potent regulatory 
function and contributing the most to CD8+ CTL exhaustion. The study has shown that 
over 50% of all Tregs were positive for TIM-3. Further they discussed the use of TIM-
3 blocking antibodies in the context of non-small cell lung cancer (NSLC) treatment. 
NSLC tumor infiltrating Tregs express high amounts of TIM-3 [126]. Regardless TIM-3 




Figure 12 Comparison of CD4+ Tregs expressing PD-1. Shown are 10 healthy 
donors (HD) and 17 OvCas. There were no detectable differences between HD 
and OvCa PBMC whereas significantly higher amounts of TILs expressed PD-1.  
Over half of tumor-infiltrating Tregs had moderate expression of PD-1 compared to 
Tregs isolated from PBMCs that did not express PD-1. CD4+CD25+CD127low Tregs 
from lung cancer patient PBMCs expressed significantly higher amounts of PD-1 than 
the healthy volunteer control group [127]. PD-1 marked dysfunctional Tregs in 
malignant gliomas where about 5% of all T cells and Tregs expressed PD-1 which 




CD4+ T helper cells play a pivotal role in the mediation of immune responses against 
infected or tumor cells. Subsequent cells were analyzed for the selected co-receptor 




Figure 13 Comparison of CD4+ non-Tregs expressing CD137. Shown are 10 
healthy donors (HD) and 17 OvCas. HD did not differ from PBMCs but TILs 
differed significantly from OvCa PBMCs. 
Comparing PBMCs and TILs, there were significant more cells expressing CD137 on 
TILs than on PBMCs. Five TIL samples showed moderate expression of around 3% to 
6% and two samples had about 8% of CD137 positive TILs. Regarding these findings 
tremendous efforts were made using stimulating agonistic antibody or 4-BB ligand and 
its variants in cancer immunotherapy. They find use in a broad spectrum of different 




Figure 14 Comparison of CD4+ non-Tregs expressing CTLA-4. Shown are 10 
healthy donors (HD) and 17 OvCas. TILs did not differ from PBMCs from HD or 
OvCa. 
Two PBMC samples with 5% and 9% CTLA-4 positive cells were outliers among the 
group while the rest of the samples remained largely negative. Among the TIL samples 
only 1 was positive for CTLA-4 (Figure 14). There is no doubt of the success of anti-
CTLA-4 blocking antibodies in different tumor types. Thus a quantification of CTLA-4 
on T helper cells still remains to be shown. In OvCa however there was only one 




Figure 15 Comparison of CD4+ non-Tregs expressing LAG-3. Shown are 10 
healthy donors (HD) and 17 OvCas. HD were negative for expression of LAG-3. 
PBMCs and TILs were also negative but some outliers were detected. The 
outliers are most probable due to unspecific binding of antibody. 
LAG-3 is known for its regulatory effects on T cell function. Patients analyzed for LAG-3 
were largely negative, whereas six samples had high amounts of LAG-3 positive cells. 
Unfortunately it remains unclear if the positive sample actual true measurements or 
artefacts caused by the antibody binding nonspecific epitopes.  
Preliminary experiments to establish the antibody panel revealed large populations of 
LAG-3 positive cells among CD4+ and CD8+ T cells on PBMCs of unstimulated healthy 
donor PBMCs. Titration experiments of LAG-3 antibodies were done in order to find 
the optimal concentration. To distinguish between a stained antibody artefact and a 
staining of LAG-3 expression, cells were pretreated for 16 hours with the strong 





Figure 16 LAG-3 Antibody titration. Cells were stained with CD45 as lymphocyte 
marker, 7-AAD to assess viability, CD4 Ab and CD8 Ab and then either with FITC-
isotype control or LAG-3 staining antibody. The first column contains the isotype 
control staining. Subsequently 1*10^6 cells were stained with increased 
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amounts of LAG-3 Ab of 0.25 µl, 0.5 µl, 2.5 µl or 5 µl with or without pretreatment 
of cells with PHA (PHA treated isotype control).  Shown is the gating for CD4 and 
CD8 followed by the gating for LAG-3. CD4+ LAG-3+ cells are shown in the 
middle row and CD8+ LAG-3+ cells in the bottom row. The titration experiment 
unveiled an unspecific binding of LAG-3 Ab by increased LAG-3 populations 
depending on amount of LAG-3 Ab used.  
The titration of LAG-3 staining Ab (Figure 16) unveiled an unspecific binding of the 
LAG-3 Ab. PHA treatment of cells lead to a stimulation of LAG-3 expression which can 
be observed throughout all titration steps. If the LAG-3 Ab would bind specifically to 
LAG-3, populations of LAG-3+ T cells would be equal in size. PHA untreated samples 
were LAG-3- (population size smaller or equal to isotype control) when stained with 
2.5 µl LAG-3 Ab or less. PHA untreated cells stained with 5 µl Ab had 6.47% and 24.7% 
of positive cells. This effect is also observed in PHA treated cells. Concluding from 
these experiments 0.5 µl LAG-3 staining Ab per 1*10^6 cells was the chosen 
concentration because PHA untreated cells were clearly negative and a LAG-3 positive 
population was observable in PHA stimulated cells.   
 
Figure 17 Comparison of CD4+ non-Tregs expressing PD-1. Shown are 10 
healthy donors (HD) and 17 OvCas. HD showed moderate expression of PD-1 but 
did not differ from OvCa PBMCs. PBMCs had significantly lower amounts of cells 
expressing PD-1 than TILs.  
 
T helper PBMCs were distributed mostly between 2% and 11% of positive cells. One 
outlier had about 18% of PD-1+ CD4+ T cells in PBMCs with about 17% positive T 
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cells respectively in the TIL sample. Among the TIL samples only four of them had TIL 
counts with less than 5% of positive cells. The remaining patients were broadly 
distributed between 5% and 23% of positive cells. The patient found positive with 38% 
of PD-1+ CD4+ positive TILs had only 4.7% of positive PBMCs, being even below the 
average of about 6%. Overall higher amounts of PD-1+ CD4+ non-Tregs were found 
in TILs compared to the respective PBMCs. A study analyzing PD-1 expression in 
follicular lymphoma described the influence of PD-1 expression on disease progress. 
PD-1 expressing cells were categorized upon high or low amounts of cells expressing 
PD-1. Overall on average 50% of CD4+ T cells were positive in follicular lymphoma 
patients. But at least 20% of all CD4+ T cells were PD-1+ which is the highest 
detectable amount of CD4+ non-Tregs in OvCa [130]. In type I diabetes patients PD-1 
expression on CD4+ T cells was correlated to different genotypes of diabetes patients. 
Each of the four analyzed genotypes had around 5% of CD4+ PBMCs. Three patients 
of the cohort had up to 10% PD-1+ CD4+ T cells [131]. These results are comparable 
to the findings in OvCa. 
 
Figure 18 comparison of CD4+ non-Tregs expressing TIM-3. Shown are 10 
healthy donors (HD) and 17 OvCas. TIM-3 was negative on TILs and low to absent 
on OvCa PBMCs but elevated level on HD. Amounts of TIM-3 HD did not differ 
significantly from OvCa PBMCs.  
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Two patients had relatively high amounts of TIM-3+ cells whereas the rest of the 
patients and the TIL sample were largely negative for TIM-3 expressing cells or 
displayed low numbers. In contrast to our findings it has been reported that a significant 
higher proportion of CD4+ T cells from OvCa tissue expressed TIM-3 than their 
respective PBMCs. Patients with high amounts of CD4+TIM-3+ T cells had significantly 




Cytotoxic T cells are often favored by immunologists because of their capability to clear 
infected or tumorous cells. In the course of development of cancer immunotherapy 
strategies these cells play pivotal roles. Therefore the OvCa samples were analyzed 
for CD8+ cytotoxic T cells and the selected markers.  
 
Figure 19 comparison of CD8+ CTL expressing CD137. Shown are 10 healthy 
donors (HD) and 17 OvCas. HD do not differ from PBMCs but there were 
significantly higher amounts of TILs compared to PBMCs.  
Comparable to the expression of CD4+ non-Tregs the expression of CD137 was 
relatively low. But comparing PBMCs to TILs showed significant differences between 
the 2 groups. The two outliers in each group are not related to each other and are from 
different patients. The Rosenberg lab addressed immune checkpoint inhibitors of 
CD8+ T cells in metastatic melanoma. It has been shown that adoptive transfer of TILs 
can lead to tumor regression. TILs of 24 tumors and 21 PBL samples of melanoma 
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patients were studied and analyzed for the expression of various surface markers. 
Comparable to our findings in OvCa PBMCs were negative for the expression of 
CD137. TILs contained significantly higher amounts of up to about 45% of CD137+ 
CTLs. The average was about 12.5% of positive cells being twice as much as in OvCa 
[133].   
 
Figure 20 comparison of CD8+ CTL expressing CTLA-4. Shown are 10 healthy 
donors (HD) and 17 OvCas. Despite two outliers CTLA-4 was not expressed by 
CTL. 
CD8+ T cells remained largely negative for the expression of the co-receptor CTLA-4 
regardless if PBMCs or TILs were analyzed. Positive PBMC samples were negative in 
the respective TIL samples and vice versa. Comparable work stimulated PBMCs of 
healthy donors with the strong activators of T cell gene expression PMA and A23187. 
Stimulation of T cells lead to an increased expression of CTLA-4 in CD4+ T cells but 




Figure 21 Comparison of CD8+ CTL expressing LAG-3. Shown are 10 healthy 
donors (HD) and 17 OvCas. Comparable to CD4+ non-Tregs HD, PBMCs and TILs 
were negative and did not differ from each other, besides the outlier that are 
most likely due to unspecific binding of antibody.  
Samples expressing high amounts of LAG-3 across PBMCs were also positive in TIL 
samples. The high amounts observed could be related to unspecific binding of the 
LAG-3 antibody. In the study of the Rosenberg lab LAG-3 was significantly higher 
expressed in TILs compared to the respective PBMCs. Overall compared to the other 
immune checkpoint inhibitors its expression was rather moderate. On average 5.7% of 




Figure 22 Comparison of CD8+ CTL expressing PD-1. Shown are 10 healthy 
donors (HD) and 17 OvCas. HD and OvCa PBMCs were comparable to each other 
and TILs had significantly higher amounts of PD-1 positive cells compared to 
PBMCs.  
The inhibitory co-receptor PD-1 was not only strongly expressed by CD4+ non-Tregs 
but also on CD8+ T cells. Among PBMCs only 3 samples were negative for the 
expression of PD-1. 12 out of 17 PBMC samples had between 5% to 13% positive 
cells. Two patients had 18% and 22% of PD-1+ PBMCs. Among TILs only one patient 
was negative for the expression of PD-1. 35% of all TIL samples were between 3.4% 
and 9.4% of positive cells. Ten samples had more than 10% of PD-1+ CD8+ T cells. 
One of them was around 40% and two even surpassed the 50% mark. In melanoma 
patients it was shown that PD-1 was expressed on average by about 32% of all TILs 
while PBLs were mostly below 10% of PD-1+ CD8+ T cells [133]. These results are 
comparable to the findings in OvCa where numbers were a little lower but the 





Figure 23 Comparison of CD8+ CTL expressing TIM-3. Shown are 10 healthy 
donors (HD) and 17 OvCas. All three groups appear heterogeneous but do not 
differ from each other.   
TIM-3 was expressed on comparable amounts of CD8+ cells as it was on CD4+ T cells. 
Patients that had high amounts of CD4+ TIM-3 positive PBMCs had also higher 
amounts of CD8+ TIM-3+ PBMCs. Most samples, regardless if PBMCs or TILs had 
fairly low amounts of TIM-3 positive cells and both groups did not differ from each other 
significantly. The Rosenberg lab determined about 13% of TIM-3+ CD8+ TILs while 
PBMCs remained negative for PD-1 expression [133]. Compared to OvCa there were 




Figure 24 Comparison of frequencies of B cells from OvCa PBMC and TIL 
samples. Shown are 16 OvCas. Within the group of TILs the amount of infiltrating 
B cells varied but overall there were no detectable differences between PBMCs 
and TILs.  
Patient samples were analyzed for the infiltration of B cells. While B cells were found 
on a physiological measure with PBMCs, five samples were negative for tumor-
infiltrating B cells. Nine of 16 samples had 2% to 7% of tumor-infiltrating B cells. Two 
samples had 8% and 12% of B cells among their lymphocytes. B cells from all PBMC 
samples have shown two distinguishable populations that varied in size. It has been 
shown that sustained engagement of the B cell receptor to the antigen is required for 
a sustained B cell activation, proliferation and survival. Upon activation B cells grow in 
size [135]. In a metastatic melanoma study tumors were subdivided in three histological 
patterns. The first pattern was not infiltrated by immune cells. The second pattern was 
characterized by immune cell infiltrates in the blood vessel proximity. The third pattern 
was distinguished by a diffuse infiltration of immune cells throughout the metastatic 
tumor. Whereas the histological pattern with the diffuse infiltration of tumor cells 
represented the group of patients with the least progression and the best survival 
prognosis. Overall 33% of tumor-infiltrating lymphocytes were B cell lineage cells and 
the second largest group after T cells with 53% of all tumor infiltrating lymphocytes 
[52]. In OvCa B cells appear in smaller amounts and are probably of minor importance 
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for the largest part of OvCas since only two of 16 were positive with around 10% B 
cells of tumor infiltrating lymphocytes.   
 
Figure 25 Comparison of frequencies of NK cells from OvCa PBMC and TIL 
samples. Shown are 16 OvCas. While PBMCs showed for the most part 
physiological amounts of NK cells, there were no detectable tumor-infiltrating 
NK cells.  
Among patients´ PBMCs there was a heterogeneous distribution of NK cells. In TIL 
samples NK cells were low abundant or absent. A study histologically analyzing tumor 
infiltrating lymphocytes in metastatic melanoma described a low presence of tumor 
infiltrating NK cells [52]. Yet only little is known about the effective function and role of 
tumor infiltrating NK cells. Despite their poor ability to produce cytokines and cytolytic 
granules (perforin and granzyme B) over a longer time course, they are able to release 
a high amount of such within a short amount of time of two to four hours [136, 137]. In 
157 colorectal cancer patients, tissue was histologically analyzed for tumor infiltrating 
NK cells. Patients were monitored for five years and NK cell infiltration was related to 
overall survival and progression free survival. Additionally NK infiltration was related to 
tumor stage. The statistical difference was significant comparing cumulative survival of 
patients with poor or moderate NK infiltration to patients with extensive infiltration 
favoring the latter. Surprisingly the statistical difference in overall survival between 
poor/moderate and extensive infiltration was observed between patients diagnosed at 
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a later stage (stage III or stage IV) and could not be observed in patients with early 
stage tumors [138]. The same observation was made in gastric cancer. Here 169 
patients were divided into two groups according to their grade of infiltration. Patients 
with highly infiltrated tumors survived significantly longer than patients with poor 
infiltration [139]. Histological analysis of squamous cell lung cancer revealed there was 
a significant difference in survival of patients. Patients with less than five tumor 
infiltrating NK cells were compared to patients with more than five NK cells per field 
using an image analyzer [140]. These findings indicate that NK cells can be very 
effective in lower numbers. So despite their poor detection rate in OvCa TILs their role 
on overall survival and tumor progression should be further addressed.  
 
Figure 26 Comparison of memory phenotype of CD4+ non-Tregs. Shown are 10 
HD and 17 OvCas. The different groups of naïve (N), central memory (CM), 
effector memory (EM) and terminally differentiated effector memory (EMRA) T 
cells are directly compared to each other. Overall HD did not show any difference 
to the PBMCs group. There is a significant shift of naïve (N) cells towards 
effector memory (EM) of TILs.  
Overall PBMCs from HD did not differ from patients’ PBMCs. PBMCs from patients 
had higher amounts of naïve and central memory T cells and moderate amounts of 
effector memory T cells. Among TIL samples there were only a few showing low or 
moderate amounts of naïve T cells. In about one third of all TIL samples patients had 
more than 50% of CM T cells. Eight of 17 samples were positive for 10% to 27% of 
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CM. Terminally differentiated EMRA CD4+ non-T cells were only very low abundant in 
all samples.     
 
 
Figure 27 Comparison of memory phenotype of CD8+ CTLs. Shown are 10 HD 
and 17 OvCa. Overall HD did not show any difference to the PBMCs group. There 
is a significant shift of naïve (N) cells towards effector memory (EM) of TILs, 
whereas there are significantly lower amounts of EMRA CTLs in TILs than 
PBMCs.  
HD PBMCs were comparable to PBMCs of patients. Six of 17 patients’ PBMC samples 
have shown below 10% of naïve T cells whereas eight samples had above 20% of 
naïve CD8+ T cells. In TIL samples none of the samples had more than 18% of positive 




The data acquired via flow cytometry were correlated to tumor progression. 
Progression data were available for 14 of the 17 patients analyzed here. Within the 
first nine months six out of eight patients showed tumor recurrence or progression. 
One patient was in complete remission 10 months after enrolment another one after 
14 months after enrolment. After 14 months one patient showed stable disease and 
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another one’s tumor recurred. The two patients that were enrolled the longest were at 
complete remission (15 months) or stable disease (17 months).  
 
Table 4 Progression data of OvCa patients analyzed by flow cytometry. The 
second column shows the time period until tumors progressed. If the patient 
did not show progression the time duration since when the patient is under 
complete remission is shown.  
OvCa ID months enrolled until diagnosis diagnosis 
OvCa 1 9 tumor recurrence 
OvCa 2 9 complete remission 
OvCa 3 10 complete remission 
OvCa 4 15 complete remission 
OvCa 5 14 complete remission 
OvCa 6 17 stable disease 
OvCa 7 9 palliative care 
OvCa 8 14 tumor recurrence 
OvCa 9 5 tumor recurrence 
OvCa 10 9 tumor progression 
OvCa 11 14 stable disease 
OvCa 12 1 supportive care, R2 resection 
OvCa 13 6 intestinal obstruction 










Figure 28 Quartiles for co-receptor expression on CD4+ Tregs of PBMCs (left) 
and TILs (right). Patients are clustered depending on their disease progression. 
Patients with malignant progression are above the black bar and patients with 
no progression are below the black bar (see table 5 for progression details). 
 
Figure 28 depicts the progression free survival data correlated to the frequency of 
coreceptor+ CD4+ Tregs. The dark blue or dark red coloring indicates that samples 
are below (dark blue) the 25% quantile or above (dark red) the 75% quantile. This 
means dark colored samples belonged to the 25% of samples with the lowest/ highest 
frequencies of positive cells.  
PBMC Treg samples of patients with malignant progression (PMP) have 15 dark blue 
colored fields. Tregs of PBMCs of patients with no progression (PNP) were six times 
below the 25% quantile. In contrast to this, patients with malignant progression were 
eight times colored dark red. Tregs of patients with no progression were observed 16 
times to have the highest amount of positive cells.  
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12 samples of tumor-infiltrating Tregs of patients with malignant progression were 
among the samples containing the highest amounts of positive cells. 9 samples of 
patients with no progression were colored dark red. Samples of ten patients were 
colored dark blue when they showed malignant progression and 13 samples when no 
progression occurred.  
Five out of seven CD137 Treg patient samples were colored in a red tone in non-
progression patients. Patients with malignant progression were in only two samples 
above the median. This indicates a minor involvement of CD137 expressed by Tregs 
in the regulation of tumor recurrence in OvCa patients. 
Four out of seven of PD-1 TIL samples of patients with no progression were located in 
the lower half of patients containing PD-1+ Tregs. One patient with malignant 
progression was characterized with low amounts of PD-1+ Tregs.  Three out of seven 
PMP had high amounts of PD-1 expressing Tregs. This results suggest a minor 
involvement of PD-1 expression on tumor infiltrating Tregs. These remaining 






Figure 29 Quartiles for co-receptor expression on CD4+ non-Tregs of PBMCs 
(left) and TILs (right). Patients are clustered depending on their disease 
progression, patients with malignant progression are above the black bar and 
patients with no progression are below the black bar (see table 5 for progression 
details). The 25% quantile is also referred to as 25% quartile and the 75% quantile 
as 75% quartile.   
Figure 29 correlates the data of disease progression to the flow cytometry results. 
Correlation was done equally to the heatmap of Figure 28.   
Across all CD4 PBMC samples, 14 of PMP samples and six samples of PNP were 
colored dark blue. 11 PMP samples were above the median with eight of them being 
colored dark red. 16 PNP samples were above the median in amounts of coreceptor 
expressing cells.  
Among TILs of PMP 12 samples were above the median (10 dark red colored) and 12 
below (nine dark blue colored). 13 samples of TILs from PNP were dark red colored 
and equally as much were dark blue colored.  
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Four of CD137 TIL samples from PNP were above the 75% quartile and three were 
below the 25% quartile. On CD137 PMP samples, only two of them were above the 
median. This indicates a correlation between disease progression and the amount of 
CD137 CD4+ T cells.   
In TIL samples both PMP and PNP contain three samples with high amounts of PD-1+ 
CD4+ T cells. Three PNP were below the 25% quartile. Three PMP TIL samples were 
below the median. Thus there was no correlation between tumor progression and PD-1 
expression.    
 
Figure 30 is a heatmap correlating the flow cytometry data of CD8+ CTLs and the 
disease progression data. Overall CD8 PBMC samples of PMP contained 16 dark blue 
fields and 9 dark red fields. Samples from PBMCs of PNP patients 12 dark red colored 
field and 7 dark blue colored fields. In TILs of PMP nine receptors were above the 75% 
quartile and ten below the 25% quartile. TILs of PNP contained ten receptors colored 
dark blue and 12 colored dark blue.  
In PMP OvCa 9 contained more CD137+ CD8+ TILs than over half of all other samples. 
In contrast to that four samples of PNP were among the 25% of samples containing 
the highest amounts of positive cells, whereas the remaining three PNP samples were 
among the lowest 25%.  
PD-1 expression on TILs four samples of PMPs had above median amounts of TILs 
expressing PD-1. In samples of PNPs only two of them were among the samples with 
the highest amounts of PD-1+ CD8+ TILs. The remaining five samples of PNPs were 





Figure 30 Quartiles for co-receptor expression on CD8+ T cells of PBMCs (left) 
and TILs (right). Patients are clustered depending on their disease progression, 
patients with malignant progression are above the black bar and patients with 
no progression are below the black bar (see table 5 for progression details). 
 
Immune checkpoint receptors were analyzed by flow cytometry using directly labeled 
monoclonal antibodies. The lymphocytes were distinguished between CD4 and CD8. 
CD4+ T cells were further distinguished into regulatory T cells and T helper cells. These 
three T cell subsets were analyzed for the expression of selected immune checkpoint 
receptors. As an additional control PBMCs of ten healthy donors were obtained and 
analyzed. PBMCs of healthy donors did not differ from PBMCs from OvCa.   
Comparing OvCa TIL and OvCa PBMC samples CD137 and PD-1 were detected in 
significantly higher amounts compared to PBMCs of the respective patient.  
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CTLA-4, TIM-3, and LAG-3 had no significant difference between OvCa PBMCs and 
OvCa TILs. 
Subsequently the data obtained from flow cytometry were correlated to disease 
progression.  For this reason flow cytometry data were divided into quartiles and 
evaluated samples based on which quartile they belong to. CD137 showed a tendency 
to positively influence progression-free survival in Tregs, T helper cells and CTLs. PD-1 
showed a tendency to positively influence progression-free survival on Tregs and 
CD8+ T cells but seems to have no influence when expressed by CD4+ T helper cells. 
Whereas a longer period of time monitoring patients might allow a better evaluation of 








As described by Schuster et al. a list of peptides and their respective source proteins 
was set up for 32 OvCa samples and 22 benign ovaries (OvN). Parts of the results 
shown here contributed to the work of Schuster et al. (table 8) [121]. Shown are the 
results either comparing OvCa to OvN or to a benign database containing different 
benign autopsy tissues. The benign database contains different samples processed by 
our department.  
 
 
Figure 31 Comparison of frequencies of source proteins of HLA class I ligands 
from OvCa (red) and OvN (blue). Source proteins found on both tissue types are 
shown in the middle section of the graph having a red and a blue counterpart. 
Source proteins of peptides exclusively presented on either tissue are found in 
the outer rims (far left for OvCa exclusive source proteins and far right for OvN 
exclusive peptides) of the graph.   
 
A waterfall plot compares the different source proteins represented on OvCa samples 
(red) and OvN samples (blue) (figure 31). Each peak represents a single source 
protein. The height of the peak shows the coverage of how many samples represented 
at least one ligand of that source protein. Source proteins on the far left that are only 
present in OvCa and have no OvN counterpart are exclusively found in OvCa but not 
on benign tissue. The other way around peptides found on the far right site that are 































ovarian tissue. The part in the middle shows source proteins that are represented by 
HLA class I ligands on both, benign and cancer tissue. In the context of cancer 
immunotherapy the far left source proteins give rise to peptides that are candidates for 




Figure 32 HLA class I presented peptides isolated from benign ovarian tissue 
(OvN in blue) in comparison to OvCa tissue (red). Comparable to figure 31 the 
middle section shows the overlap between both tissues meaning peptides that 
were found on both tissue types. On the far right OvN peptides are exclusively 
found on benign ovarian tissue.  
In Figure 32 the peptides originating from the source proteins depicted in Figure 31 are 
shown. Each peak represents a single peptide and the height of the peak is the 
frequency of how many samples presented that peptide. The peptides on the left hand 
side are exclusively presented on HLA class I of OvCa tissue compared to the benign 

































Figure 33 Comparison of source proteins of OvCa and a benignome database. 
The overlap of the OvCa and the benignome dataset accounts for 63.3% of the 
source proteins identified. 3.1% of the datasets entered were OvCa exclusively 
presented source proteins.  
The OvCa source proteins were compared to a database containing source proteins 
of different autopsies of kidney, lung, muscle, small intestine, spleen, bladder, brain, 
cerebellum, heart, pancreas, skin, stomach, thyroid, adrenal gland, aorta brain, 
esophagus, liver, testis, bone marrow, tongue, colon and PBMCs. 485 OvCa-unique 
proteins were identified. These 485 also contain the 56 source proteins described by 





Figure 34 Overlap of OvCa HLA class I peptides and the HLA class I benignome 
database. 8.6% of the OvCa peptide database was tumor exclusively presented.  
To find ligands suitable for peptide based anti-cancer vaccine the amount of HLA class 
I ligands represented exclusively on OvCa tissue were further narrowed in. Therefore 
the 56 HLA class I and the 28 HLA class II source proteins described by Schuster et 
al. were reduced [121]. To reduce the number of target source proteins the frequency 
of representation on OvCa, their known involvement in the development or progression 
of OvCa or other tumor entities and the amount of ligands per source protein were 
taken into account. Under these criteria 13 proteins presented by HLA class I and 4 
proteins presented by HLA class II proteins were chosen.  
The HLA typing of OvCa samples was acquired from the university hospital. The online 
tools SYFPEITHI and NetMHC 4.0 utilize the HLA typing to evaluate the binding 
probability or binding affinity of ligands to the respective HLA type of the sample. 
SYFPEITHI is a database that facilitates search for peptides and allows T-cell epitope 
prediction. The prediction is based on published motifs. It takes amino acids in the 
anchor, auxiliary anchor positions and frequent amino acids into consideration. The 
amino acids of peptides are given a specific value. Ideal anchors are scored with 10 
points, unusual anchors 6-8 points, auxiliary anchors 4-6 points and preferred residues 
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are scored with 1-4 points. Amino acids that are having a negative effect on the binding 
ability score values of -1 to -3 points [141]. Additionally NetMHCpan-3.0 predicted the 
binding affinity of MHC: peptide binding. NetMHC is a neural network to predict HLA 
class I epitopes. The methods for prediction of binding to HLA are trained on peptide 
data containing information about the binding affinity of the peptide to the HLA [142]. 
Ligands with ≥ 60% of maximum SYFPEITHI score or a binding affinity of ≤ 500 nM on 
NetMHC were considered probable binders.    
The ligands of the 13 HLA class I and the four HLA class II source proteins are listed 
in the supplemental data (table 9 and table 10). It needs to be mentioned that up to 
now there is no reliable evaluation tool for HLA class II peptides and their predicted 
binding.  
A large scale study searched for clinically relevant peptide presented by human 
melanoma tissue. Utilizing MS analysis, the melanoma associated immunopeptidome 
was surveyed in depth for about 78,000 HLA class I patient presented peptides which 
is twice as much as we identified in OvCa (> 40900 peptides) [143]. The difference in 
numbers is related to technical differences in the processing and analysis of tissue. 
Equally to our procedure HLA class I molecules were immunoaffinity purified using the 
W6/32 antibody covalently bound to a protein A sepharose matrix. However the 
antibody used for HLA class II immunoaffinity purification was HB-145. For the LC-
MS/MS analysis of HLA peptides, they were eluted with a linear gradient of 2-30% 
buffer B (80% ACN and 0.5% acetic acid). The flowrate was set to 250 nl/min over 
90 min. The column used for elution was 50 cm long and 75 µm in diameter. In contrast 
the duration of one LC-MS/MS run in our lab lasts 130 min with a linear gradient for 90 
min. The peptides were eluted with a linear gradient 2.4-32% ACN and 0.05% formic 
acid (fa). The applied flow rate was 300 nl/min. The separation column is 25 cm long 







The first patients under compassionate use setup were treated three days prior to 
vaccination with cyclophosphamide to reduce the amount of regulatory T cells. On the 
first day the patient received subcutaneous injection of Ipilimumab at low dose because 
of its effects on Tregs and its priming supportive effect. Imiquimod was applied on site 
of vaccination after every vaccination. Each vaccination contained 300 µg of each 
peptide regardless if HLA class I or HLA class II restricted. The peptides were dissolved 
in 500 µl DMSO. The patient was vaccinated three times starting day zero, one 
vaccination a day. Following, vaccination number four occurred on day seven followed 
by 2 more vaccinations once every week. Two weeks after the sixth vaccination, the 
patient was vaccinated again, followed by another vaccination on day 49. For the 
remaining time up to one year duration, the patient received 16 vaccination shots every 
three weeks. Throughout the course of vaccination blood was collected and used for 
immunomonitoring purposes. The therapy was prolonged by additional 4 vaccines 
every 6 weeks. The peptide cocktail was injected intracutanously in order to be 
processed by professional APCs such as Langerhans cells. Throughout the 
vaccination the patient received Avastin on a frequent basis in between the peptide 
vaccination appointments as a standard therapy. Table 2 contains the peptides 
administered to the first patient (ID: OvCa 115) and the source proteins they are 
originating from. Table 2 also contains the number of positively tested T cell primings. 
The peptide SVLADVTTK was synthesized with the wrong sequence. The original 
sequence was SVLADLVTTK. Therefore the peptide was not further assessed in 
immunomonitoring. The HLA class II peptide ELGPYTLDRNSLYVNG could not be 






Table 5 Vaccination peptides of OvCa 115, the first patient to be vaccinated in 
compassionate use treatment. The peptides and their respective source proteins 
are listed below. HLA restriction and the amount of positive immunogenicity 
testings is listed respectively.  The ten peptides were combined in one cocktail.  
vaccination peptides  
OvCa 115 
  HLA class I    
source protein  peptide sequence  immunogenicity  HLA restriction 
MUC16  SVLADVTTK  A*03 
IDO1  RSYHLQIVTK  1/1  A*03 
EYA2  NVGGLIGTPK  0/1  A*03 
MUC16  SPHPVTALL  2/3  B*07 
MUC16  SPSKAFASL  3/3  B*07 
MUC16  TPGNRAISL  5/5  B*07 
MUC16  VPRSAATTL  2/3  B*07 
IDO1  NPKAFFSVL  3/5  B*07 
 
 HLA class II 
 longest variant   core peptide  prediction 
MSLN  DLPGRFVAESAEVLLPR FVAESAEVLL  SB to DRB3*0101, WB DRB1*1302 






Figure 35 HLA class I mediated reactions at the different time points blood was 
drained from the patient. PHA control has shown stimulation potential of cells. 
The numbers in the upper left corner of each well indicates the counted spots 
respectively. 
 
There were no detectable HLA class I mediated reactions in the ELISpot. Due to a lack 
of cells after the 12-day stimulation peptide mixes were set up for cells obtained on 
day 21, 49 and 196. The peptides RSYHLQIVTK and NVGGLIGTPK were combined 
and analyzed. Likewise the SPHPVTALL and the SPSKAFASL, as well as the 
TPGNRAISL together with VPRSAATTL and the NPKAFFSVL peptide were combined. 
The final concentration for each peptide was unchanged at 1 µg/ml. A well was 
considered to display a positive reaction if a minimum of 15 spots was counted and the 
count must be three times higher than the count of the negative well (negative peptide 
or medium control). HLA matched virus peptides were used as negative controls. The 
virus peptides were either published before or predicted from different viruses. 
KIRLRPGGK is a HIV peptide that was published before to not induce a detectable 
immune response [144]. They were tested for their ability to induce HLA class I/II 
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mediated reactions. They were tested in at least eight healthy donors and did not 
induce an immune response.   
The HLA class II restricted vaccination peptides were combined and analyzed 
together. A strong immune reaction was observed on day 21. However this reaction 
was strikingly reduced by day 49 and lost on day 196.  
 
Figure 36 HLA class II immunomonitoring of patient 1. The two vaccination 
peptides were analyzed together within the same well due to low availability of 
PBMCs.  
 
Subsequently in the second round of immunomonitoring Figure (37/38), due to low cell 
counts after 12-day stimulation vaccination peptides were mixed similarly as described 
above (Figure 35/36). PHA stimulated control was positive. HLA-class I peptides failed 




Figure 37 Immunomonitoring of OvCa 115 at later time points between 386 and 
534 days of vaccination. PHA control induced T cell responses but HLA class I 
vaccination peptides failed to do so. 
The 12-day stimulation for HLA-class II restricted vaccination peptides did not show an 





Figure 38 HLA class II mediated reaction of OvCa 115. The analyzed PBMCs were 
obtained 386-534 days after first vaccination. There were no detectable HLA 
class II mediated reactions.  
 
A second patient (OvCa 100) was analyzed under the same protocol as the first one. 
The cocktail was composed of six HLA class I peptides and two HLA class II peptides 
from the warehouse. From preliminary work from our lab ExomeSeq data were 




Table 6 List of vaccination peptides of OvCa 100. It consists of six HLA class I 
peptides and two HLA class II peptides from the warehouse. Two peptides were 
predicted from exome sequencing (ExomeSeq) containing a point mutation at 
the indicated position. 
vaccination peptides 
OvCa 100   
  HLA class I    
source protein   peptide sequence  immunogenicity  HLA restriction 
MUC16  KMISAIPTL  4/6  A*02 
MUC16  SPHPVTALL  1/2  B*07 
MUC16  SPSKAFASL  2/2  B*07 
MUC16  TPGNRAISL  2/2  B*07 
IDO1  NPKAFFSVL  3/5  B*07 
DDR1  FLAEDALNTV  n/a  A*02 
   
 HLA class II   










MUC16  SLTHELSSRV  p.T2285S  A*02 
PLEKHG2  PGGGAPASSRGSWSS  p.A1303S  HLA class II 
 
Each vaccination peptide was tested separately. At day 21 an immune reaction was 
detectable by ELISpot against the MUC16 peptide SPSKAFASL with about 150 
counted spots. At day 49 up to 700 spots were counted showing an even stronger 
immune reaction to this peptide. Other wells of vaccination peptides of day 49 were 
not accounted as positive since negative because of on average 15 spots of the wells 






Figure 39 Immunomonitoring of HLA class I mediated T cell responses in OvCa 
100. The SPSKAFASL peptide showed an immune response 21 days after the 
first vaccination. 
 
Two HLA-class II peptides, DLPGRFVAESAEVLLPR (MSLN) and 
ELGPYTLDRNSLYVN (MUC16) have induced positive wells at day 21. Both reactions 
were strong with about 500 and 700 counted spots.  The reaction of 
DLPGRFVAESAEVLLPR (MSLN) at day 49 was clearly reduced with about 300 
detected spots. On the other hand the reaction of ELGPYTLDRNSLYVN (MUC16) was 




Figure 40 HLA class II restricted vaccination peptide immunomonitoring of OvCa 
100. The MSLN peptide induced a strong response that was weaker on day 49. 
The reaction against the MUC16 peptide was clearly detectable on day 21 but 
vanished completely by day 49. 
 
The patient discontinued the treatment due to disease progression but reentered 403 
days after first vaccination. Besides the positive reaction against PHA there were no 




Figure 41 HLA class I peptides immunomonitoring of OvCa 100. She continued 
vaccination procedure at a later time point (403 days after first vaccination). 
There were no detectable HLA class I mediated reactions. Reactions that were 
visible on day 21 could not be recovered on later time points of vaccination.  
 
The early HLA-class II mediated reaction shown in Figure 40 could not be recovered 




Figure 42 HLA class II peptide immunomonitoring of patient 2 after continued 
vaccination. Similar to HLA class I immune reactions detectable during early 
days of vaccination were not recovered in later stages of vaccination.  
 
In order to improve performance of the peptide-based anti-cancer vaccine the 
treatment protocol was altered. For this purpose the 500 µl of peptide cocktail were 
emulsified in 1 ml Montanide ISA-720™, a plant oil based adjuvant. Since Montanide™ 
ISA-720™ has a depot effect on the vaccinated peptides the amount of injections was 
reduced and vaccination was applied subcutanously. Again three days prior to 
vaccination low dose cyclophosphamide was given in order to reduce regulatory T 
cells. The first four vaccinations were given every three weeks and following injections 
were given every 8 weeks. The subcutanous application is more patient friendly and 
easier to inject. Ipilimumab was removed from the setting due to no visible effect. 





Table 7 List of vaccination peptides for OvCa 134. Five HLA class I restricted 




source protein  sequence  immunogenicity  HLA restriction 
MUC16  ERSPVIQTL n.t.   B*39 (B*27) 
MUC16  ITETSAVLY 1/2  A*01 
CRABP2  NVMLRKIAV 0/1  B*08 
CRABP1/2  RTTEINFKV 1/2  A*02 
CTAGE5  VGREKKLAL n.t.  B*08 
   
 HLA class II 









The third patient (OvCa 134) had weak T-cell responses to ERSPVIQTL. Nevertheless 
the reaction seemed to be preexisting since it was detectable at day 0. The immune 
reaction prevailed until day 63. All wells containing PBMCs isolated on day 21 had a 
background reaction that was visible in well treated with vaccination peptides as well 
in wells treated with negative control peptide or of the medium control. A possible 
explanation for this can be that a high percentage of cells may have underwent cell 





Figure 43 Immunomonitoring of HLA class I mediated reactions of OvCa 134. A 
pre-existing response was detected against the MUC16 ERSPVIQTL peptide.  
 
In the case of HLA-class II reaction the patient had a vaccine-induced reaction starting 
on day 21 in the DLPGRFVAESAEVLLPR (MSLN) treated wells. A weak pre-existing 
reaction against the ELGPYTLDRNSLYVN (MUC16) peptide was detectable before 
the first vaccine was administered. Furthermore there was a very strong reaction 




Figure 44 HLA class II mediated reactions of patient OvCa 134. The DPPA2 
peptide induced a strong induction of immune response by day 21 which 
persisted until day 63. The MSLN peptide stimulated reactive T cells on day 21 
and day 63 but weaker on day 42 indicating a restimulation of cells.  
It remains unknown if the weaker reaction on day 42 is due to homoestatic 
downregulation of T cells or if stimulated cells at day 21 infiltrated the peripheral tissue 
and therefore where not detectable within PBMCs. 
A study conducted by the Wu lab was published in the course of this year. The study 
was designed for melanoma patients. Utilizing whole exome sequencing of benign and 
tumor tissue, somatic mutations were identified. RNA sequencing confirmed the 
expression of mutated alleles. Subsequently peptides were predicted to bind 
autologous HLA-A or HLA-B molecules. Peptides were synthesized as long peptides 
(15-30 amino acids long). Hiltonol, a known TLR3 antagonist, was used as an 
adjuvants. Patients were vaccinated with 13-20 peptides. Patients received seven 
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vaccinations all in all, of which five were administered within the first four weeks of 
treatment, one at week 12 and one at week 20. The readout of the study was done via 
ex vivo ELISpot. They were capable of showing a strong induction of T cell responses, 
whereas clinical response was detectable in only two out of six patients. Thus the 
remaining four patients had no tumor recurrence for at least 21 months after 
vaccination [145].   
Comparable to our findings in OvCa the antigenic landscape of multiple myeloma was 
assessed by mass spectrometry in our department. The HLA ligandome of PBMCs 
from multiple myeloma patients and multiple myeloma cell lines was analyzed. PBMCs 
from healthy donors and MM patients were pulsed with MM-associated peptides. In 
the course of the study pre-existing, peptide-specific T cell responses were 
characterized exclusively in myeloma patients indicating the pathophysiological 
relevance of the identified peptides [146]. 
The aims of this thesis were to characterize the expression of immune checkpoint 
inhibitors CD137, CTLA-4, LAG-3, PD-1 and TIM-3 of CD4+ Tregs, non-Tregs and CTL 
in PBMCs and TILS of OvCa tissue. PD-1 was significantly higher expressed on TILs 
than on PBMCs or PBMCs of healthy donors. The author of this thesis contributed 
further MS analysis of OvCa and OvN tissue deepening the understanding of the OvCa 
ligandome and finding peptides suitable for therapeutic treatment of OvCa patients. 
These peptides have been administered in compassionate use treatment of three 
















































































































































































































































































































































































































































































Figure 45 Gating strategy for the PBMC isotype control. In the first pictures the 
gate is set on cells to distinguish them from debris. The second picture shows 
the single cell gate followed by the viability staining with 7-AAD (negative 
staining). The lymphocyte gate was set on CD45 and side scatter (SSC) to 
distinguish lymphocytes from monocytes. Originating from the CD4+ cells, cells 
were gated for their expression of CD25/CD127 to determine the amount of Tregs 
(CD25+ CD127low). The memory phenotype was assessed via CCR7 and CD45RO. 
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Q1 is characterized as naïve T cells, followed clockwise by central memory (Q2), 






Figure 46 Gating strategy for PBMCs oriented on the isotype control staining of 





















Figure 49 Gating strategy of the second panel, staining for NK cells (NKp46), B 
cells (CD19) and tumor cells (CD45- EpCAM+). In PBMCs the CD19 gate contains 
two small populations differing in size. B cells increase in size upon 







Table 8 sample IDs of HLA ligandome analyzed OvCas (left column) and OvN 
(right column). The list below contains all samples processed by the author of 






































Table 9 Peptide sequences for each derived from the 13 proteins that were 
considered for peptide-based immunotherapy of OvCa patients. Table organized 
for proteins and uniprot accession ID. The amount of OvCas the peptide was 
isolated from is another parameter to evaluate the relevance of the peptide for 
warehouse. These peptide sequences were all presented on OvCa tumor tissue 
processed by the author of this thesis. Sequences might overlap with 
preliminary work.   
protein accession sequence # of OvCa IDs 
MUC16 Q8WXI7 AEITITTQTGY 1 
 
 AESIPTVSF 4 
 
 AETILTFHAF 1 
 
 AHSKITTAM 1 
 
 DALTPLVTI 3 
 
 DALVLKTV 2 
 
 DPYKATSAV 3 
 
 EAYSSTSSW 1 
 
 EPETTTSFITY 1 
 
 ERSPVIQTL 2 
 
 ETILTFHAF 3 
 
 ETTASLVSR 1 
 
 EVISSRGTSM 1 
 
 EVPSGATTEVSR 2 
 
 EVYPELGTQGR 1 
 
 FAVPTGISM 3 
 
 FESHSTVSA 1 
 
 FPFVTGSTEM 1 
 
 FPHSEETTTM 1 
 
 FPHSEITTL 1 
 
 FPHSEMTTV 2 
 
 FQRQGQTAL 1 
 
 FSTDTSIVL 1 
 
 GEPATTVSL 1 
 
 GHESHSPAL 1 
 
 GSDTSSKSL 1 
 
 GVATRVDAI 1 
 
 HESEATASW 1 
 
 HETETRTTW 3 
 




 HLTEVYPEL 1 
 
 HQFITSTNTF 2 
 
 IEHSTQAQDTL 1 
 
 IITEVITRL 1 
 
 IPGPAQSTI 1 
 
 IPRVFTSSI 4 
 
 IQIEPTSSL 1 
 
 ISDEVVTRL 4 
 
 ISVPAKTSL 1 
 
 ITETSAVLY 2 
 
 ITRLPTSSI 1 
 
 KMISAIPTL 4 
 
 KTFPASTVF 2 
 
 LPHSEITTL 1 
 
 LPTSESLVSF 1 
 
 LYVDGFTHW 1 
 
 MPNLPSTTSL 1 
 
 NLSSITHER 1 
 
 PGGTRQSL 1 
 
 PLLVLFTI 1 
 
 QAKTHSTL 1 
 
 QFITSTNTF 2 
 
 QRFPHSEM 1 
 
 QSTPYVNSV 1 
 
 RETSTSEETSL 1 
 
 RETSTSQKI 1 
 
 RPLFQKSSM 2 
 
 RVFTSSIKTK 1 
 
 RVRSTISSL 3 
 
 SAFESHSTV 3 
 
 SAIETSAVL 2 
 
 SAIPFSmTL 1 
 
 SATERSASL 1 
 
 SEPDTTASW 3 
 
 SEQRTSPSL 1 
 
 SESVTSRTSY 1 
 
 SETPVGASI 1 
 
 SEVPLPMAI 1 
 




 SIKTKSAEM 1 
 
 SPAGEAHSL 2 
 
 SPAMTSTSF 1 
 
 SPFSAEEANSL 2 
 
 SPGATSRGTL 1 
 
 SPHPVSTTF 2 
 
 SPHPVTALL 4 
 
 SPHPVTALLTL 3 
 
 SPLFQRSSL 1 
 
 SPMATTSTL 1 
 
 SPMTSLLTSGL 1 
 
 SPQNLRNTL 4 
 
 SPQSMSNTL 1 
 
 SPRFKTGL 1 
 
 SPRLNTQGNTAL 4 
 
 SPRTEASSAVL 2 
 
 SPSEAITRL 2 
 
 SPSKAFASL 7 
 
 SPSPVSSTL 2 
 
 SPSSPMSTF 1 
 
 SPSSPTPKV 1 
 
 SQGFSHSQM 3 
 
 SRTEISSSR 1 
 
 SRTEVASSR 1 
 
 SRTEVISSR 2 
 
 SSETTKIKR 1 
 
 STETSTVLY 1 
 
 STIPALHEI 1 
 
 STSQEIHSATK 1 
 
 STTFPTLTK 1 
 
 SVLADLVTTK 1 
 
 SVLTSSLVK 1 
 
 SVSGVKTTF 2 
 
 SVSSETTKIKR 2 
 
 SVTESTHHL 1 
 
 TAGPTTHQF 4 
 
 TAKTPDATF 1 
 
 TEARATSDSW 1 
 




 TETEAIHVF 6 
 
 TEVSRTEAI 1 
 
 THSAMTHGF 1 
 
 THSTASQGF 1 
 
 THSTISQGF 1 
 
 TPGGTRQSL 4 
 
 TPGLRETSI 2 
 
 TPGNRAISL 6 
 
 TPKLRETSI 1 
 
 TSDFPTITV 1 
 
 TSGPVTEKY 1 
 
 TSHERLTTL 1 
 
 TSIFSGQSL 1 
 
 TSMPRSSAM 1 
 
 TSRSVDEAY 1 
 
 TTALKTTSR 1 
 
 TTYEGSITV 1 
 
 TVAKTTTTF 2 
 
 TYSEKTTLF 3 
 
 VPRSAATTL 2 
 
 VPTPVFPTM 1 
 
 VSKTTGMEF 1 
 
 YPDPSKASSAM 4 
 
 VLQGLLRSL 1 
CRABP1/2 P29373;P29762 FYIKTSTTV 1 
 
 MLRKIAVAA 1 
 
 NAMLRKVAV 1 
 
 NVMLRKIAV 3 
 
 RTTEINFKV 8 
 
 VAAASKPAV 1 
IDO1 P14902 LELPPILVY 2 
 
 NPKAFFSVL 6 
 
 NPSVREFVL 1 
 
 RSYHLQIVTK 7 
 
 RYMPPAHRNF 4 
 
 TLLKALLEI 3 
MMP11 P24347 APAAWLRSA 3 
 
 APAAWLRSAA 3 
 




 FPRLVGPDF 1 
 
 GRADIMIDF 1 
 
 GRWEKTDLTY 1 
 
 HEFGHVLGL 1 
 
 LLQPPPLLAR 1 
 
 LPSPVDAAF 2 
 
 RPASSLRP 2 
 
 VRFPVHAAL 1 
 
 VRFPVHAALVW 1 
 
 VWSDVTPLTF 7 
 
 YTFRYPLSL 3 
PTTG1/2 O95997 DAYPEIEKF 1 
 
 FPFNPLDF 2 
 
 FPFNPLDFE 1 
 
 SPSSILSTL 3 
EYA2 O00167 AELEALTDLW 2 
 
 ETIIIFHSL 3 
 
 NEIERVFVW 8 
 
 NVGGLIGTPK 10 
 
 RVKEMYNTY 2 
 
 SVFPIENIY 1 
LGALS1 P09382 APDAKSFVL 1 
 
 AVFPFQPGSV 1 
 
 EVAPDAKSF 2 
 
 FPFQPGSV 2 
 
 FPNRLNLEA 1 
 
 GEVAPDAKSFVL 1 
 
 LPDGYEFKF 1 
 
 YEFKFPNRL 3 
FOLR1 P15328 NPNEEVARF 2 
 
 NPNEEVARFY 2 
 
   
KLK10 O43240 RALAKLLPL 7 
 
 VLVDQSWVL 3 
TMEM158 Q8WZ71 GRAFFAAAF 2 
 
 KPIESTLVA 1 
 






Table 10 HLA class II eluted peptides of the tumor-exclusive ligandome. Three 
different proteins are shown with mesothelin (MSLN), MUC16 and DPPA2. 
protein  accession  sequence  # of OvCa IDs 
MSLN  Q13421  AEVLLPRLV  1 
   AIPFTYEQLDVLKHKLDE  1 
   ALGGLACDLPGRFVAES  1 
   ALRGLLPVLGQPI  1 
   ALRGLLPVLGQPII  1 
   ALRGLLPVLGQPIIR  3 
   ALRGLLPVLGQPIIRS  1 
   ALRGLLPVLGQPIIRSIPQ  1 
   ALRGLLPVLGQPIIRSIPQG  1 
   ALRGLLPVLGQPIIRSIPQGIVA  1 
   APERQRLLPAALA  1 
   AVLPLTVAEVQKLLGPHVEG  2 
   AVRPQDLDTCDPR  2 
   DALRGLLPVLGQPIIR  1 
   DALRGLLPVLGQPIIRS  2 
   DALRGLLPVLGQPIIRSIP  1 
   DALRGLLPVLGQPIIRSIPQ  3 
   DALRGLLPVLGQPIIRSIPQG  2 
   DALRGLLPVLGQPIIRSIPQGIVA  2 
   DLPGRFVAESA  1 
   DLPGRFVAESAEVL  1 
   DLPGRFVAESAEVLL  3 
   DLPGRFVAESAEVLLP  4 
   DLPGRFVAESAEVLLPR  11 
   EADVRALGG  1 
   ERHRPVRDWILRQRQ  1 
   ERVRELAVALAQKNVK  1 
   EVQKLLGPHVEG  1 
   EVSGLSTER  1 
   FLKMSPEDIRK  1 
   FMKLRTDAVLPL  1 
   FmKLRTDAVLPLT  2 
   FMKLRTDAVLPLTVA  1 
   FVKIQSFLG  1 
   FVKIQSFLGG  1 
   FVKIQSFLGGAPT  2 
   GGIPNGYLVL  1 
   GIVAAWRQRSSRDPS  1 
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   GLLPVLGQPIIR  1 
   GLLPVLGQPIIRSIPQGIVA  3 
   GLLPVLGQPIIRSIPQGIVAA  1 
   GLLPVLGQPIIRSIPQGIVAAWRQ  2 
   GLSTERVRELAVALAQ  1 
   GLSTERVRELAVALAQKN  1 
   GQPIIRSIPQGIV  1 
   GQPIIRSIPQGIVA  4 
   GSLLSEADVRA  1 
   GSLLSEADVRALG  2 
   GSLLSEADVRALGG  2 
   GSLLSEADVRALGGL  3 
   GVRGSLLSEADVRAL  1 
   GVRGSLLSEADVRALG  1 
   GVRGSLLSEADVRALGG  3 
   GVRGSLLSEADVRALGGL  3 
   GVRGSLLSEADVRALGGLA  3 
   IPFTYEQLDVLKHKLD  1 
   IPFTYEQLDVLKHKLDE  2 
   IPFTYEQLDVLKHKLDELYPQ  1 
   IPQGIVAAWRQRSSR  1 
   IPQGIVAAWRQRSSRDPS  2 
   IWAVRPQDLDTCDPR  1 
   LGLQGGIPNGYLVL  1 
   LGQPIIRSIPQGIVA  4 
   LGQPIIRSIPQGIVAA  1 
   LKALLEVNKGHEMSPQ  1 
   LLPVLGQPIIRSIPQGIVA  1 
   LLPVLGQPIIRSIPQGIVAA  1 
   LLSEADVRALG  1 
   LLSEADVRALGG  1 
   LPGRFVAESAEVL  1 
   LPGRFVAESAEVLL  3 
   LPGRFVAESAEVLLP  5 
   LPGRFVAESAEVLLPR  10 
   LPLTVAEVQKLLGPHVEG  1 
   LPLTVAEVQKLLGPHVEGLK  1 
   LPVLGQPIIRSIPQGIVA  5 
   LPVLGQPIIRSIPQGIVAA  1 
   LPVLGQPIIRSIPQGIVAAW  1 
   LPVLGQPIIRSIPQGIVAAWRQ  1 
   LQGGIPNGYLVL  2 
   LQGGIPNGYLVLDL  1 
   LRGLLPVLGQPI  1 
   LRGLLPVLGQPIIR  2 
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   LRGLLPVLGQPIIRS  1 
   LRGLLPVLGQPIIRSIPQ  1 
   LRGLLPVLGQPIIRSIPQG  1 
   LRGLLPVLGQPIIRSIPQGIVA  1 
   LRGLLPVLGQPIIRSIPQGIVAA  1 
   LRTDAVLPLTVAEVQKLLGPHVEG  1 
   LSEADVRALGG  1 
   LSTERVRELAVALAQ  1 
   LSTERVRELAVALAQK  1 
   LSTERVRELAVALAQKN  2 
   LSTERVRELAVALAQKNVK  1 
   LTVAEVQKLLG  1 
   LTVAEVQKLLGPHVEG  1 
   LTVAEVQKLLGPHVEGL  1 
   LTVAEVQKLLGPHVEGLK  1 
   LTVAEVQKLLGPHVEGLKA  1 
   LTVAEVQKLLGPHVEGLKAE  1 
   LTVAEVQKLLGPHVEGLKAEE  2 
   LTVAEVQKLLGPHVEGLKAEER  1 
   LTVAEVQKLLGPHVEGLKAEERHRP 1 
   MDALRGLLPVLGQPIIRSIPQGIVA  1 
   PGRFVAESAEVLLPRL  1 
   PVLGQPIIRSIPQGIVA  4 
   PVLGQPIIRSIPQGIVAAW  1 
   QPIIRSIPQGIVA  1 
   RELAVALAQKNVKLSTE  1 
   RGLLPVLGQPI  1 
   RGLLPVLGQPIIR  1 
   RGLLPVLGQPIIRSIPQGIVA  1 
   RGLLPVLGQPIIRSIPQGIVAAWRQ  1 
   RGSLLSEADVRALG  2 
   RGSLLSEADVRALGG  2 
   RTDAVLPLTVAEVQKLLGPHVEG  1 
   RVRELAVALAQKNVK  1 
   SEADVRALGG  1 
   SLLSEADVRALG  1 
   SPRQLLGFPCAEVSG  1 
   TERVRELAVALAQKN  1 
   TFMKLRTDAVLPLTVA  1 
   TLGLGLQGGIPNGYLV  1 
   TVAEVQKLLGPHVEG  3 
   TVAEVQKLLGPHVEGL  1 
   TVAEVQKLLGPHVEGLK  2 
   VAEVQKLLGPHVE  1 
   VAEVQKLLGPHVEG  6 
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   VAEVQKLLGPHVEGL  1 
   VAEVQKLLGPHVEGLK  1 
   VLDLSMQEA  1 
   VLGQPIIRSIPQGIVA  2 
   VLPLTVAEVQKLLGPHVEG  1 
   VLPLTVAEVQKLLGPHVEGLK  1 
   VLPLTVAEVQKLLGPHVEGLKAEE  1 
   VPPSSIWAVRPQDLDTCDPR  3 
   VQKLLGPHVEG  3 
   VRELAVALAQKNVK  1 
   VRGSLLSEADVRA  1 
   VRGSLLSEADVRALG  6 
   VRGSLLSEADVRALGG  4 
   VRGSLLSEADVRALGGL  3 
   VRGSLLSEADVRALGGLA  2 
   VSTMDALRGLLPVLGQPIIR  1 
   VSTMDALRGLLPVLGQPIIRSIPQ  1 
   VSTMDALRGLLPVLGQPIIRSIPQG  1 
   VTSLETLKALLEVNK  1 
   WGVRGSLLS  1 
   WGVRGSLLSEADVR  1 
   WGVRGSLLSEADVRA  1 
   WGVRGSLLSEADVRAL  1 
   WGVRGSLLSEADVRALG  2 
   WGVRGSLLSEADVRALGG  2 
   WGVRGSLLSEADVRALGGL  3 
   WGVRGSLLSEADVRALGGLA  3 
MUC16  Q8WXI7  ATTEVSRTEAISFSR  1 
   ATTPSWVETHSIVIQGFPH  1 
   DKAFTAATTEVSR  1 
   EELGPYTLDRNSLYVNG  1 
   EITITTQTGYSLATSQVTLP  1 
   ELGPYTLDRDSLYVN  1 
   ELGPYTLDRNSL  1 
   ELGPYTLDRNSLYV  1 
   ELGPYTLDRNSLYVN  2 
   ELGPYTLDRNSLYVNG  2 
   ETILTFHAF  1 
   FDKAFTAATTEVSR  2 
   FDKAFTAATTEVSRTE  1 
   GIKELGPYTLDRN  1 
   GIKELGPYTLDRNSL  1 
   GIKELGPYTLDRNSLYVNG  1 
   GLLKPLFKSTSVGPL  1 
   GPYTLDRNSLYVN  1 
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   GPYTLDRNSLYVNG  2 
   GSRKFNTMESVLQGLL  1 
   IELGPYLLDRGSLYVNG  1 
   INNLRYMADMGQPG  2 
   ISTRTVSWFSTSPV  1 
   LAQSMRSSDSPSEAIT  1 
   LGFYVLDRDSLFIN  1 
   LGPYLLDRGSLYV  1 
   LGPYLLDRGSLYVN  1 
   LGPYLLDRGSLYVNG  1 
   LGPYTLDRNSL  1 
   LGPYTLDRNSLY  1 
   LGPYTLDRNSLYV  2 
   LGPYTLDRNSLYVN  4 
   LGPYTLDRNSLYVNG  3 
   LKPLFKSTSVGPL  1 
   LKPLFKSTSVGPLY  1 
   LKPLFKSTSVGPLYS  1 
   LKPLFKSTSVGPLYSG  1 
   LLKPLFKSTSVGPL  1 
   LRPVFKNTSVGPL  1 
   LVTSSRAVTST  1 
   NLQYSPDmGKGSATFNSTE  1 
   QLGFYVLDRDSLFIN  1 
   QVTLPLGTSMTFLSGT  1 
   RTGSRKFNTMESVLQGLL  1 
   SASLPTPGQSLNTIPDSDAS  1 
   SDPYKATSAVVITS  1 
   SDPYKATSAVVITST  1 
   SRKFNTMESVLQG  1 
   SRKFNTMESVLQGLL  1 
   SSGYKSQSSVLADS  1 
   STETITRLSTFPFVT  1 
   STETITRLSTFPFVTG  1 
   STQRVTTSMIMDTVE  1 
   SVPDILSTSW  1 
   THGIKELGPYTLDRN  1 
   TLDRNSLYVN  1 
   TLDRNSLYVNG  1 
   TPSWVETHSIVIQG  1 
   TPSWVETHSIVIQGFP  1 
   TPSWVETHSIVIQGFPH  2 
   TRKIIKFPTSPI  1 
   TSTVYWATTGTPSSFP  1 
   TTPSWVETHSIVIQGFP  1 
118 
 
   TTPSWVETHSIVIQGFPH  2 
   TTSVPSVVSGFTTLK  1 
   WELSQLTNSVTELGPYTLDRD  1 
   WPSPPFVKETSPPSSPL  1 
   WVETHSIVIQGFPH  1 
DPPA2  Q7Z7J5  RLLSADTKGWVRLQ  1 
 









DRB1*13:03:01, DRB1*15:01:01:01, DRB3*01:01:02:01, 
DRB5*01:01:01, DQB1*03:01:01, DQB1*06:02:01, DQA1*01:02:01, 
DQA1*05:01:01, DPB1*03:01:01 DPB1*05:01:01 
3  OvCa134 
A*01:01;A*02:01;B*08:01;B*39:01;C*07:01;C*12:03, DQB1*02:01, 





Table 12 warehouse of OvCa exclusive peptides that can be used for peptide-
based anti-cancer vaccines. Peptides are organized based on their HLA 
restriction. Additionally immunogenicity assessed by aAPC priming, the amount 
of OvCas the peptide was represented on and the OvCa IDs are shown. OvCas 
with an ID of 99 or higher are contributed by the author of the thesis.  





A*01  ITETSAVLY  MUC16  1 / 2  3 OvCa 111 OvCa 134 OvCa 65                 
A*02  TLLKALLEI  IDO1     4 OvCa 99 OvCa 132 OvCa 137 OvCa 140           



















A*02  IITEVITRL  MUC16  3 / 10  1 OvCa 126                   














































A*24  QFITSTNTF  MUC16  2 / 3  4 OvCa 60 OvCa 118 OvCa 121 OvCa 153           






A*25  EVITSSRTTI  MUC16  1 / 1  1 OvCa 141                   




A*25  EVTSSGRTSI  MUC16  2 / 3  2 OvCa 107 OvCa 111                  













A*68  EVPSGATTEVSR  CA125     2 OvCa 105 OvCa 110                  
A*68  EVPTGTTAEVSR  CA125     2 OvCa 105 OvCa 110                  
B*07  APRPASSL  MMP11     3 OvCa 107 OvCa 126 OvCa 136                 


































B*13  AVTNVRTSI  MUC16     3 OvCa 132 OvCa 137 OvCa 140                 
B*15  SQGFSHSQM  MUC16  5 / 6  3 OvCa 131 OvCa 157 OvCa 162                 








B*18  LELPPILVY  IDO1     2 OvCa 116 OvCa 128                  










B*27  GRAFFAAAF  TMEM158     2 OvCa 103 OvCa 128                  
B*27  GRSQVSTPRF  PTTG1/PTTG2     1 OvCa 53                   
B*27  QRMTTQLLL  FOLR1     1 OvCa 103                   
B*27  SRTEVISSR  MUC16     3 OvCa 53 OvCa 103 OvCa 110                  
B*35  LPSPVDAAF  MMP11     3 OvCa 104 OvCa 65 OvCa 121                 
B*35  DAYPEIEKF  PTTG1/PTTG2     8
OvCa 53 OvCa 54 OvCa 58 OvCa 110 OvCa 
120 OvCa 121 OvCa 132 OvCa 150            
B*35  NPSVREFVL  IDO     3 OvCa 13 OvCA 104 OvCa 109 












B*35  LPHSEITTL  MUC16     4 OvCa 12 OvCa 13 OvCa 121 OvCa 135              






























B*44  NEIERVFVW  EYA2     1 OvCA 139 (Zystadenom)                   
B*51  FPFQPGSV  LGALS     2 OvCa 141 OvCa 130                  




B*51  DPYKATSAV  MUC16  3 / 3 
7
OvCa 10 OvCa 41 OvCa 69 OvCa 73 OvCa 74 
OvCa 79 PC2011‐14             
 
 
